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Adipose tissue; the new central metabolic system 
Until the identification of Leptin in 1994 1, adipose tissue had been considered as 
the organ that reserves excessive energy as fat.  However, it is now well recognized that 
adipose tissue plays a dynamic role in metabolic regulation as a new central metabolic 
system.  First, adipose tissue is able to sense metabolic states through its ability to 
perceive a large number of neuronal and hormonal signals.  For example, both 
sympathetic and parasympathetic neurons from the central nervous system (CNS) 
innervate adipose tissue and regulate the activity of enzymes.  Both control hormone-
sensitive lipase activity in adipocytes, and this lipase activity in turn regulates glucose 
and lipid uptake into adipocytes in opposing ways 2,3.  Secondly, adipose tissue is also 
able to secrete various endocrine and paracrine hormones, commonly referred to as 
adipokines.  The endocrine functions of adipokines allow the adipocytes to regulate 
cellular processes in peripheral tissues such as liver and pancreas, and in CNS such as the 
hypothalamus 4.  Leptin, the first adipokine identified by Jeffrey M. Friedman and his 
colleagues, acts on receptors in the hypothalamus of the brain 1, where it controls body 
weight homeostasis.  This process is mediated by decreasing hunger and food 
consumption at least in part by inhibition of neuropeptide Y (NPY) synthesis, a very 
potent stimulator of feeding behavior, and by increasing energy expenditure through 
activation of sympathetic neurons 5.  The paracrine effects of adipokines have an impact 
on neighboring adipocytes, as well as other local cell types within adipose tissue, such as 
immune cells.  Proinflammatory cytokine tumor necrosis factor-α (TNF-α), known to be 
produced chiefly by activated macrophages, is secreted by enlarged adipose tissues in 
excess nutrient conditions, and neutralization of TNF-α showed improved insulin 
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sensitivity by diet-induced obesity 6.  By activating Inhibitor of κB kinase-β (IKK) and 
Jun N-terminal kinases (JNKs) which inhibit the insulin signaling pathway, TNF-α 
increases lipolysis and decreases glucose uptake in adipose tissues 7-10.  TNF-α also has 
been recognized as a powerful driving force to activate adipose tissue macrophages 
(ATMs), leading to the secretion of a variety of proinflammatory cytokines from ATMs 
such as TNF-α itself, and setting up a feed-forward inflammatory process 11-13.  
Communicating with other tissues as aforementioned, adipose tissue affects nutrient 
intake, metabolism, and energy expenditure, and finally plays an important role in 
pathophysiology of several diseases including obesity, diabetes, cancers, and 
inflammatory disorders. 
 In this thesis, I will introduce one more communication method of adipose tissue, 
Nicotinamide phosphoribosyltransferase (Nampt).  Nampt catalyzes the condensation of 
nicotinamide with 5-phosphoribosyl-1-pyrophosphate (PRPP) to yield nicotinamide 
mononucleotide (NMN), the rate-limiting step in nicotinamide adenine nucleotide (NAD) 
biosynthesis in mammals 14.  It is of special interest that Nampt is also secreted by 
adipose tissue and circulates through the body in the blood stream 15.  Even though at 
least three different functions have been assigned to extracellular Nampt (eNampt) 
including a cytokine-like, an insulin-mimetic, and an enzyme function that catalyzes the 
production of NMN, the physiological role of eNampt has been a matter of much debate.  
There is also little work that demonstrates how eNampt is secreted from adipocytes, and 
what distinguishes intracellular Nampt (iNampt) and eNampt at the molecular level.  
Here, in this chapter, I will briefly recapitulate the research story of Nampt and 
summarize its unique function in different biological contexts.  In the following chapters, 
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I will discuss the importance of iNAMPT in metabolically active tissues on the onset of 
age- or diet-induced type 2 diabetes, and also explain a sophisticated mechanism of 
eNAMPT secretion from adipose tissue and its physiological significance on regulation 
of glucose metabolism.  
 
History of Nampt; from cytokine to enzyme  
Nampt was originally cloned from a human peripheral blood lymphocyte cDNA 
library as a presumptive cytokine shown to enhance the maturation of B cell precursors in 
the presence of Interleukin-7 (IL-7) and stem cell factor (SCF), therefore named as pre B 
cell colony-enhancing factor (PBEF) 16.  Seven years later, when the gene encoding the 
bacterial Nampt (nadV) was first isolated in the prokaryote Hemophilus ducreyi, it was 
found to display significant homology to the mammalian PBEF genes 17.  In addition, 
through genetic approaches, Rongvaux et al. also demonstrated that the mouse PBEF 
gave Nampt enzymatic activity and NAD-independent growth to bacteria lacking nadV, 
suggesting that PBEF had NAD biosynthesis enzymatic activity at least within the cells 
18.  Nampt protein is expressed ubiquitously almost in all tissues, however several tissues 
such as pancreas and brain have relatively lower expression levels of Nampt compared to 
other tissues 15,19.  It is also highly conserved, with orthologs in bacteria, invertebrate 
sponges, Drosophila, amphibians (Xenopus), fish, bird (chicken), and mammals 14,17,20-22.    
Interestingly, since the report of PBEF, several papers have suggested a cytokine-
like function for eNampt.  First of all, when Samal and colleagues first identified PBEF, 
they reported that although PBEF lacks a characteristic signal peptide necessary for 
extracellular secretion of mature protein, the 3’ untranslated region (UTR) contains 
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multiple TATT motifs, a characteristic of cytokines, and that it is present in conditioned 
medium from activated lymphocytes and COS cells 16.  In line with this study, eNampt 
has been reported to have an important role in pro-inflammatory and immunomodulatory 
responses as a cytokine.  Nampt belongs to a group of genes defined by an immune 
“activating signature” being widely expressed within the immune system and increased in 
virtually all activated immune cells including T cells, B cells, monocytes, magrophages, 
dendritic cells, and neutrophils 23.  eNampt was found to increase under inflammatory 
conditions, and recombinant forms of Nampt have been shown to exert an anti-apoptotic 
role on activated neutrophils.  Jia et al. have found that eNampt/PBEF expression is 
upregulated by inflammatory stimuli such as lipopolysaccharide (LPS), IL-1β, and TNF-
α in neutrophils and monocytes in vitro, and in neutrophils harvested from critically ill 
patients with sepsis, a complex clinical syndrome that results from an activated systemic 
host inflammatory response to infection 24.  They have also demonstrated that eNampt 
inhibits neutrophil apoptosis in response to a variety of inflammatory stimuli, but this 
effect seems to be partially dependent on iNampt.  Similarly, Li et al. have also 
demonstrated that eNampt potently blocks macrophage apoptosis induced by a number of 
ER stressors, a process associated with obesity and obesity-associated diseases, through 
IL-6/Stat3 cell-survival pathway 25.  Interestingly, the ability of eNampt to trigger this 
anti-apoptotic effect was independent of its enzymatic activity, implying a non-enzymatic 
mechanism presumably through an undefined eNampt receptor.           
It has been also suggested that eNampt has insulin-like activity.  Fukuhara at al. 
demonstrated that eNampt can directly bind to insulin receptor and activate downstream 
signaling cascades, resulting in similar biological effects in vitro and in vivo on 
  6 
adipogenesis, cellular glucose uptake and blood glucose levels 26. They also found that 
Nampt is enriched in the visceral fat of both humans and mice and that its plasma levels 
increase during the development of obesity. Therefore, they re-identified Nampt as a 
“new visceral fat-derived hormone” named visfatin.  Although their results immediately 
drew significant attention in the field metabolism and diabetes research, subsequent 
studies have produced conflicting results regarding the physiological significance of 
visfatin function, and the original visfatin paper has been retracted because of concerns 
on the reproducibility of the results 27.   
Our lab has clearly reconstituted a mammalian NAD biosynthesis pathway from 
nicotinamide using recombinant Nampt and nicotinamide/nicotinic acid mononucleotide 
adenylyltransferase (Nmnat), another important enzyme in mammalian NAD 
biosynthesis which converts NMN to NAD, and analyzed enzymological features of this 
NAD biosynthetic pathway within the cells 14.  By using biochemical analysis, we have 
demonstrated that the catalytic efficiency of NAMPT is almost 50 times lower than 
NMNAT even though NAMPT has very high affinity for its substrate.  Consistently, 
overexpression of Nampt significantly increased total cellular NAD in mouse fibroblasts 
while increased doses of Nmnat were unable to increase NAD, suggesting that Nampt is 
the rate-limiting enzyme in mammalian NAD biosynthesis in the cells.  The 
enzymological features and the crystal structures of NAMPT have also been studied 
extensively.  Wang et al., and Kim et al., have recently resolved the crystal structure of 
mouse and rat NAMPT 28,29.  Both groups reported that functional NAMPT forms a 
homodimer composed of two identical subunits, both of which contribute to the active 
site that catalyzes the conversion of nicotinamide and phosphoribosyl-pyrophosphate to 
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form NMN.  Although NAMPT has no substantial sequence identity to other 
phosphoribosyltransferase enzymes, comparison of the sequence of the rat NAMPT 
dimer active site with that of 13 different organisms revealed the high degree of 
conservation of the sequence of amino acid residues responsible for the nicotinamide 
(substrate) and NMN (product)-binding abilities 28.  Most recently, we have demonstrated 
that NAMPT functions as an NAD biosynthetic enzyme extracellularly as well as 
intracellularly 15.  Female Nampt+/- mice, but not male, showed moderately impaired 
glucose tolerance and a significant defect in glucose stimulated insulin secretion (GSIS).  
Interestingly, whereas tissue iNAMPT and NAD levels were reduced both in Nampt+/- 
male and female mice, plasma eNAMPT and NMN, the product of the Nampt reaction, 
were reduced only in female Nampt+/- mice, and indeed insulin secretion defects in 
female Nampt+/- mice were corrected by NMN administration.  These data imply that 
systemic NAD biosynthesis, mediated by eNAMPT, has a crucial role in controlling β 
cell function in pancreatic islets for the regulation of glucose homeostasis.  In addition, 
most recently, we have observed that Nampt-mediated NAD biosynthesis is 
compromised in metabolic organs of high fat diet-induced and age-induced diabetic mice, 
and NMN administration improved glucose metabolism and insulin sensitivity of these 
mice, supporting the idea that increasing systemic NAD biosynthesis could be an 
effective intervention against diet- and age-induced type 2 diabetes 30.  In these studies, 
we proposed that all of these effects of NMN administration on improving diet- and age-
induced type 2 diabetes are mediated, at least partially, through the activity of the NAD-
dependent protein deacetylase, Sirt1.  
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Multiple functions of NAD 
NAD is one of the oldest molecules in the history of biochemistry.  A century 
ago, pellagra, which is characterized by a darkly pigmented skin rash and the three D’s of 
dermatitis, diarrhea, and dementia, was common among the rural poor in the southern 
United States.  However, in 1914, Joseph Goldberger hypothesized that pellagra might be 
caused by a poor nutrition and discovered that substitution of corn-based diet to milk, 
eggs, and meat cured and prevented this disease 31.  In 1937, Conrad Elvehjem finally 
identified Niasin, also known as vitamin B3, containing nicotinamide and nicotinic acid, 
as the key molecule to cure pellagra 32.  After a year, he also provided the evidence that 
this vitamin was used for synthesizing NAD 32.  
NAD has been primarily known as a coenzyme that is involved in redox reactions, 
carrying electrons from one reaction to another. Once NAD accepts electrons from other 
molecules, it becomes reduced as NADH, which can be used as reducing agent to donate 
electron 33.  Recycling back and forth between the oxidized form (NAD) and reduced 
form (NADH), cells rely on NAD to maintain basic cellular reactions such as glucose and 
fatty acid metabolism, respiration, and photosynthesis 34 35.   
In addition to a coenzyme, NAD also acts as a substrate for three other classes of 
enzymes, ADP-ribose transferases (ARTs) or poly(ADP-ribose) polymerases (PARPs), 
cADP-ribose synthases, and Sirtuins (type III protein lysine deacetylases) 33.  ARTs and 
the more numerous, PARPs transfer the ADP-ribose group from NAD onto acceptors 
such as arginine, glutamic acid, or aspartic acid to create an ADP-ribosyl protein 
modification and/or to form the ADP-ribose polymer, referred as mono-ADP-ribosylation 
and poly-ADP-ribosylation, respectively 36,37.  Although mono-ADP-ribosylation has 
  9 
been observed in many prokaryotic and eukaryotic species and in viruses, the biological 
functions of this reaction have been more closely characterized from bacterial toxins 
since mono-ADP-ribosylation is responsible for the actions of several bacterial toxins 
such as cholera, diphtheria, pertussis, and clostridial toxins.  These toxin proteins are 
ARTs which modify crucial host cell target proteins like the α−subunit of heterotrimeric 
GTP binding proteins, the small GTPase Rho, monomeric actin and eukaryotic 
elongation factor 2(eEF2), resulting in permanent activation or inactivation of cell 
functions modulated by these protein substrates 37.  The mono-ADP-ribosylation 
reactions induced by these bacterial toxins are an important part of the pathogenic 
mechanisms that cause cholera, botulism and other diseases. In vertebrates, mono-ADP-
ribosylation also can be applied to their own endogenous target proteins such as integrins, 
defensin, β−subunit of heterotrimeric G proteins, and GRP78/BiP, through which cell 
signaling and cellular metabolism are regulated 37. 
Different from mono-ADP-ribosylation, poly-ADP-ribosylation occurs in many 
multicellular organisms including plants and some lower unicellular eukaryotes, but is 
absent in prokaryotes and yeast.  PARPs are mainly localized in the nucleus and involved 
in DNA repair and programmed cell death.  For instance, in an immediate cellular 
response to metabolic, chemical, or radiation-induced single strand DNA breaks (SSB) 
damage, PARP-1 binds to SSB and begins the synthesis of poly-ADP-ribose chain as the 
signal for other DNA repairing enzymes such as topoisomerase I and II, NAD helicases, 
single-strand-break repair (SSBR) and base-excision repair (BER) factors. Strong 
activation of PARP-1 by DNA damage may deplete the storage of cellular NAD and 
induce a progressive ATP depletion, leading to apoptotic or necrotic cell death 36.    
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 cADP-ribose synthases, also known CD38 and CD157, are a pair of 
multifunctional ecto-enzymes which are involved in the catabolism of NAD and NADP 
38.  This reaction leads to the generation of potent intracellular Ca2+ mobilizing 
compounds such as cyclic ADP ribose (cADPR), nicotinic acid adenine dinucleotide 
phosphate (NADDP), and ADPR 39.  The importance of these enzymatic pathways has 
been demonstrated not only in the immune system, but also in tissues and organs, such as 
pancreas and kidney.  In innate immunity, neutrophiles and dentritic cells (DCs) are 
critical regulators of innate and adaptive immune responses, respectively.  Neutrophils 
and DCs obtain the capacity of directionally migrating to the site of infection through 
modulating cADPR-induced Ca2+ mobilization into the cells, suggesting that CD38 is 
required for the chemotaxis of neutrophils and DCs 39.  Similarly in islet microsomes, 
cADRP is generated by glucose stimulation in islets and serves as a second messenger for 
Ca2+ mobilization in the endoplasmic reticulum, resulting in induction of insulin secretion 
40.    
 
NAD-dependent Sirtuins; the link from NAD to metabolic syndrome 
 Sirtuins are the class III histone deacetylase family, and require NAD as a 
cofactor to deacetylate target proteins and modify their function 41.  Sirtuins couple the 
breakdown of NAD with deacetylation and/or ADP-ribosylation on lysine residues of 
target proteins, and nicotinamide, acetyl-ADP-ribose, and deacetylated proteins are 
produced in these NAD-dependent deacetylation reactions41-43.  The first member of the 
Sirtuin family of proteins to be identified was the Saccharomyces cerevisiae NAD- 
dependent histone deacetylase silent information regulator 2, SIR2 41.  As the name 
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implies, the SIR2 gene was originally discovered as one of the genes that encode a 
chromatin-silencing complex, which represses gene transcription in the coding region of 
chromosomes as well as telomreres and ribosomal DNA (rDNA) repeats 44-47.  
Subsequent work showed that Sir2 was necessary and sufficient to prolong the replicative 
lifespan of budding yeast by reducing the number of extrachromosomal rDNA circles 48.  
Sir2 orthologous genes in the nematode Caenorhabditis elegans (sir-2.1) and in the fruit 
fly Drosophila melanogaster (Sir2) also function to increase lifespan 49-51. 
 Numerous target proteins, including histones and a variety of transcription factors 
and co-activators, have already been reported for Sirtuins in different species, and these 
roles of Sirtuins are also conserved in mammals.  In mammals, seven sirtuin family 
members, SIRT1 through SIRT7, have been identified.   SIRT1, SIRT6, and SIRT7 are 
mainly localized in the nucleus of most cell types and regulate metabolism at multiple 
levels 52, even though SIRT1 is reported to be also localized in cytoplasm depending on 
cell cycle and developmental stage 53-56.  SIRT2 is mostly found in the cytoplasm, 
whereas SIRT3, SIRT4, and SIRT5 are primarily localized in mitochondria 52.   In 
addition to deacetylase activity, SIRT4 and SIRT6 were reported to function as ADP-
ribosyltransferases, even though SIRT6 also can act as a deacetylase 52.  
The most-studied member of the mammalian sirtuin family is SIRT1, which was 
originally described to deacetylate histones but soon after was also shown to deaceylate 
other protein targets in almost all tissues.  The first-described non-histone target is p53, 
which is deaceylated and repressed upon DNA damage or oxidative stress, resulting in 
impaired apoptosis 57,58.   Peroxisome-activated receptor-γ co-activator 1α (PGC1α), 
which is a transcriptional co-regulator that governs mitochondrial biogenesis and activity, 
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is also deacetylated and activated by SIRT1 during exercise or fasting, resulting in 
upregulation of the transcription of genes responsible for mitochondrial biogenesis and 
fatty acid oxidation in skeletal muscle 59-61.  In addition, SIRT1 regulates hepatic 
metabolism at multiple levels.  First of all, SIRT1 orchestrates the activity of an array of 
transcription factors that can alter hepatic glucose output during fasting.  SIRT1 
deacetylates and activates PGC1α, PPARα, and FOXO1, which induces the expression 
of genes whose products are involved in gluconeogenesis, fatty acid oxidation, and 
mitochondrial biogenesis 59,62,63.  SIRT1 also deacetylates and inhibits STAT3, which 
normally acts as a transcriptional repressor of gluconeogenic genes 64.   Secondly, SIRT1 
can induce the liver to shut off lipid and cholesterol synthesis and storage, and activates 
lipolysis pathways to supply the fasting organism with energy.  Deacetylation of sterol 
regulatory element binding protein 1 (SREBP1) by SIRT1 results in targeting of SREBP1 
for ubiquitination and proteasomal degradation, which inhibits the expression of 
lipogenic and cholesterol synthesis genes 65,66.  SIRT1 also promotes reverse cholesterol 
transport by deacetylating and activating the oxysterol receptor (LXRα) 67, and promotes 
the cholesterol catabolic pathway by deacetylating and activating nuclear bile acid 
receptor (FXR) 68.   
SIRT1 also plays a crucial role in counteracting many features of metabolic 
syndrome.  SIRT1 has an inhibitory effect on adipocyte differentiation and fat tissue 
accumulation by inhibiting the activity of PPARγ, the master regulator of adipogenesis 69.  
SIRT1 also augments insulin secretion in response to glucose in pancreatic β cells by 
repressing the transcription of uncoupling protein 2 (UCP2) 54,70.  SIRT1 achieves this 
effect on UCP2 expression by directly binding to and repressing UCP2 gene transcription 
  13 
in pancreatic β cells 70.  By deacetylating FOXO1 in response to oxidative stress caused 
by hyperglycemia, SIRT1 also mediates protection against hyperglycemia-induced 
toxicity and failure of pancreatic β cells 71.  In the brain, SIRT1 acts in pro-
opiomelanocortin (POMC) neurons in the hypothalamus to regulate energy expenditure 
and body weight 72-74.  Additionally, SIRT1 activity in neurons that express steidorgenic 
factor 1 (SF1) has a protective role against the development of insulin resistance in 
skeletal muscle in response to a high-fat diet through the mediating anti-diabetic effects 
of the neuropeptide orexin A 75.         
   Different from SIRT1, SIRT2 is mainly found in cytoplasm.  SIRT2 deacetylates 
tubulin 76, but the relevance of this is unclear.  More importantly, SIRT2 also deacetylates 
partitioning defective 3 homologue (PAR3), which, in turn, decreases the activity of the 
cell polarity to control the protein atypical protein kinase C (aPKC), thereby changing 
myelin formation of Schwann cells 77.  In addition, SIRT2 may have roles in metabolic 
homeostasis by deacetylating phosphoenolpyruvate carboxykinase (PEPCK), which is 
involved in gluconeogenesis, and thereby preventing its ubiquitylation-dependent 
degradation 78.  SIRT2 also deacetylates and inactivates FOXO1, resulting in inhibition of 
adipocyte differentiation 79.  
  SIRT3 functions in mitochondria as a metabolic sensor by regulating adaptive 
responses to changes in available energy.  In response to fasting, SIRT3 protein levels 
and activity are upregulated in the liver and in turn acetylate several mitochondrial 
proteins. These acetylated proteins include long-chain acyl-coenzyme A dehydrogenase 
(LCAD), a key enzyme in the fatty acid oxidation pathway 80, and 3-hydroxy-3-
methyglutaryl CoA synthase 2 (HMGCS2), the rate-limiting enzyme in the synthesis of 
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the ketone β-hydroxybutyrate 81, which increases their enzymatic activity.  By-products 
of lipid oxidation such as acetate and the ketone body β-hydroxybutyrate are exported 
from the liver and used for energy production in other peripheral tissues.  SIRT3 also 
deacetylates acetyl-CoA synthetase (AceCS) in peripheral tissues to generate acetyl-CoA 
from acetate, which can be consumed in the TCA cycle 82,83.  Another link between 
SIRT3 and the adaptive response to fasting is the regulation of the urea cycle, which 
clears away ammonia produced by protein breakdown during conditions of energy 
limitation.  SIRT3 promotes the urea cycle by deacetylating and activating ornithine 
transcarbamoylase 84.  
 SIRT3 is also essential for calorie restriction-mediated reduction in oxidative 
stress.  During calorie restriction, SIRT3 activates superoxide dismutase 2, a key 
mitochondrial antioxidant enzyme that converts reactive oxygen species (ROS) such as 
superoxide (O2) into hydrogen peroxide (H2O2) 85.  Moreover, calorie restriction induces 
SIRT3-mediated deacetylation of isocitrate dehydrogenase 2 (IDH2) in various tissues 
including inner ear cells, and in turn increases the ratio of reduced to oxidized 
glutathione, thus attenuating ROS generation 86.  As a result, calorie restriction protects 
against age-associated hearing loss in a SIRT3-dependent manner 86.  These results 
suggest that SIRT3 might be an important factor for the beneficial aspects of calorie 
restriction. Indeed, in the absence of SIRT3, the reduction in oxidative stress normally 
observed during calorie restriction is lost 85,86. 
 In contrast to the other sirtuins which all have deacetylase activities, SIRT4 only 
seems to have NAD-dependent ADP ribosyl transferase acitivity.  SIRT4 ADP-
ribosylates glutamate dehydrogenase (GDH) and inhibits its activity, thereby blocking 
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acmino acid-induced insulin secretion 42.  SIRT4 also regulates fatty acid oxidation in 
hepatocytes and myocytes, and short hairpin RNA (shRNA)-mediated knockdown of 
Sirt4 in the liver increases fatty acid oxidation 87.  The only target described for SIRT5 is 
carbamoyl phosphate synthetase 1 (CPS1).  By deacetylating it, SIRT5 activates 
ammonia detoxification through the urea cycle 88.  Interestingly, SIRT3 and SIRT5 
regulate different steps in the urea cycle, to clear away ammonia and prevent its toxic 
effects in conditions of nutrient limitation.              
SIRT6 is mainly involved in processes related to chromatin and regulates several 
pathways of cellular metabolism.  It can regulate chromatin by acting as a co-repressor, 
deacetylating lysine 9 of histone H3 at NF-κB signaling, which results in suppression of 
NF-κB activity and inhibition of apoptosis and cellular senescence 89,90.  SIRT6 also has a 
key role in glucose homeostasis through co-repression of HIF-1α that encodes glycolytic 
enzymes in the liver and skeletal muscle 91.  SIRT7, probably the least studied of the 
sirtuins, localizes to the nucleolus and activates RNA polymerase I transcription 92,93.  
SIRT7 whole body KO mice develop inflammatory cardiomyopathy and die prematurely 
93.  
 
Goals of this study 
Based on current understanding on NAD biosynthesis via NAMPT and its effects on 
regulating metabolism through multiple NAD-dependent enzymes including sirtuins, 
several important questions arise.  First, I want to understand the physiological functions 
of NAMPT.  Is NAMPT expression and/or activity changed under pathophysiological 
conditions such as in diet-induced diabetic or aged animal models?  If so, in which tissues 
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does this occur, and does this result in a deleterious metabolic phenotype in the animal?  
Would this metabolic phenotype be related to the NAD biosynthetic activity of NAMPT? 
Can it be reversible with inducing NAD biosynthesis by NMN administration?  Secondly, 
I am interested in the function of eNAMPT especially secreted from adipose tissues.  Is 
eNAMPT not released from cell death, but positively secreted from adipocytes?  If so, 
when is its secretion increased or decreased?  Would any post-translational modification 
be involved in eNAMPT secretion?  If there is any, which protein is related in this and 
what is the detailed molecular mechanism?  Lastly, what is the physiological importance 
of eNAMPT secreted from adipose tissue?  Using a genetically engineered mouse model, 
adipose tissue-specific Nampt KO (ANKO) mice, we will try to present evidence 





Figure 1. NAD biosynthesis pathway from nicotinamide. 
The rate-limiting step in mammalian NAD biosynthesis from nicotinamide is the 
transfer of a phosphoribosyl residue from 5-phosphoribosyl-1-pyrophosphate (PRPP) to 
nicotinamide catalyzed by nicotinamide phosphoribosyltransferase (NAMPT) to 
produce nicotinamide nomonucleoride (NMN), which is then converted to nicotinamide 
adenine dinucleotide (NAD) by nicotinamide mononucleotide adenylyltransferase 
(NMNAT). 
ATP; adenosine triphosphate, PPi; inorganic pyrophosphate 
  
Figure 2. NAD as a substrate for ADP-ribose transfer, cADP-ribose synthesis and 
protein lysine deacetylation.   
ADP-ribose transferases (ARTs) and poly(ADP-ribose) polymerases (PARPs) transfer 
ARP-ribose from NAD as a protein modification with production of nicotinamide.  In 
the case of PARPs, the ADP-ribose acceptor, X, can also be ADP-ribose, forming 
poly(ADP-ribose).  cADP-ribose synthases cyclize the ADP-ribose moiety of NAD 
with production of nicotinamide.  These enzymes also hydrolyze cADP-ribose.  
Sirtuins use the ADP-ribose moiety of NAD to accept the acetyl modification of a 
protein lysine, forming deacetylated protein and nicotinamide.  After acetyl-group 
rearrangement, a mixture of 2’ and 3’ O-acetyl-ADP-ribose are produced.  
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 Table 1  
 
  
WAT; white adipose tissue
  21 
REFERENCES 
1. Zhang, Y., et al. Positional cloning of the mouse obese gene and its human 
homologue. Nature 372, 425-432 (1994). 
2. Bamshad, M., Song, C.K. & Bartness, T.J. CNS origins of the sympathetic nervous 
system outflow to brown adipose tissue. Am J Physiol 276, R1569-1578 (1999). 
3. Bartness, T.J. & Bamshad, M. Innervation of mammalian white adipose tissue: 
implications for the regulation of total body fat. Am J Physiol 275, R1399-1411 
(1998). 
4. Lago, F., Gomez, R., Gomez-Reino, J.J., Dieguez, C. & Gualillo, O. Adipokines as 
novel modulators of lipid metabolism. Trends Biochem Sci 34, 500-510 (2009). 
5. Williams, K.W., Scott, M.M. & Elmquist, J.K. From observation to experimentation: 
leptin action in the mediobasal hypothalamus. Am J Clin Nutr 89, 985S-990S (2009). 
6. Uysal, K.T., Wiesbrock, S.M., Marino, M.W. & Hotamisligil, G.S. Protection from 
obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389, 
610-614 (1997). 
7. Yin, M.J., Yamamoto, Y. & Gaynor, R.B. The anti-inflammatory agents aspirin and 
salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77-80 (1998). 
8. Cai, D., et al. Local and systemic insulin resistance resulting from hepatic activation 
of IKK-beta and NF-kappaB. Nat Med 11, 183-190 (2005). 
9. Hirosumi, J., et al. A central role for JNK in obesity and insulin resistance. Nature 
420, 333-336 (2002). 
  22 
10. Tuncman, G., et al. Functional in vivo interactions between JNK1 and JNK2 
isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 103, 10741-
10746 (2006). 
11. De Taeye, B.M., et al. Macrophage TNF-alpha contributes to insulin resistance and 
hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab 293, E713-
725 (2007). 
12. Suganami, T., Nishida, J. & Ogawa, Y. A paracrine loop between adipocytes and 
macrophages aggravates inflammatory changes: role of free fatty acids and tumor 
necrosis factor alpha. Arterioscler Thromb Vasc Biol 25, 2062-2068 (2005). 
13. Weisberg, S.P., et al. Obesity is associated with macrophage accumulation in adipose 
tissue. J Clin Invest 112, 1796-1808 (2003). 
14. Revollo, J.R., Grimm, A.A. & Imai, S. The NAD biosynthesis pathway mediated by 
nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J 
Biol Chem 279, 50754-50763 (2004). 
15. Revollo, J.R., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as 
a systemic NAD biosynthetic enzyme. Cell Metab 6, 363-375 (2007). 
16. Samal, B., et al. Cloning and characterization of the cDNA encoding a novel human 
pre-B-cell colony-enhancing factor. Mol Cell Biol 14, 1431-1437 (1994). 
17. Martin, P.R., Shea, R.J. & Mulks, M.H. Identification of a plasmid-encoded gene 
from Haemophilus ducreyi which confers NAD independence. J Bacteriol 183, 
1168-1174 (2001). 
18. Rongvaux, A., et al. Pre-B-cell colony-enhancing factor, whose expression is up-
regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a 
  23 
cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32, 3225-3234 
(2002). 
19. Kitani, T., Okuno, S. & Fujisawa, H. Growth phase-dependent changes in the 
subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 544, 74-78 
(2003). 
20. McGlothlin, J.R., et al. Molecular cloning and characterization of canine pre-B-cell 
colony-enhancing factor. Biochem Genet 43, 127-141 (2005). 
21. Muller, W.E., et al. Increased gene expression of a cytokine-related molecule and 
profilin after activation of Suberites domuncula cells with xenogeneic sponge 
molecule(s). DNA Cell Biol 18, 885-893 (1999). 
22. Fujiki, K., Shin, D.H., Nakao, M. & Yano, T. Molecular cloning and expression 
analysis of the putative carp (Cyprinus carpio) pre-B cell enhancing factor. Fish 
Shellfish Immunol 10, 383-385 (2000). 
23. Shaffer, A.L., et al. Signatures of the immune response. Immunity 15, 375-385 
(2001). 
24. Jia, S.H., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in 
experimental inflammation and clinical sepsis. J Clin Invest 113, 1318-1327 (2004). 
25. Li, Y., et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic 
interleukin-6/STAT3 signaling mechanism. J Biol Chem 283, 34833-34843 (2008). 
26. Fukuhara, A., et al. Visfatin: a protein secreted by visceral fat that mimics the effects 
of insulin. Science 307, 426-430 (2005). 
27. Fukuhara, A., et al. Retraction. Science 318, 565 (2007). 
  24 
28. Wang, T., et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic 
enzyme. Nat Struct Mol Biol 13, 661-662 (2006). 
29. Kim, M.K., et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 
1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer 
agent FK-866. J Mol Biol 362, 66-77 (2006). 
30. Yoshino, J., Mills, K.F., Yoon, M.J. & Imai, S. Nicotinamide mononucleotide, a key 
NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in 
mice. Cell Metab 14, 528-536 (2011). 
31. Bollet, A.J. Politics and pellagra: the epidemic of pellagra in the U.S. in the early 
twentieth century. Yale J Biol Med 65, 211-221 (1992). 
32. Elvehjem, C.A., Madden, R.J., Strong, F.M. & Wolley, D.W. The isolation and 
identification of the anti-black tongue factor. 1937. J Biol Chem 277, e22 (2002). 
33. Belenky, P., Bogan, K.L. & Brenner, C. NAD+ metabolism in health and disease. 
Trends Biochem Sci 32, 12-19 (2007). 
34. Heineke, D., et al. Redox Transfer across the Inner Chloroplast Envelope Membrane. 
Plant Physiol 95, 1131-1137 (1991). 
35. Rich, P.R. The molecular machinery of Keilin's respiratory chain. Biochem Soc 
Trans 31, 1095-1105 (2003). 
36. Schreiber, V., Dantzer, F., Ame, J.C. & de Murcia, G. Poly(ADP-ribose): novel 
functions for an old molecule. Nat Rev Mol Cell Biol 7, 517-528 (2006). 
37. Corda, D. & Di Girolamo, M. Functional aspects of protein mono-ADP-ribosylation. 
EMBO J 22, 1953-1958 (2003). 
  25 
38. Malavasi, F., et al. CD38 and CD157 as receptors of the immune system: a bridge 
between innate and adaptive immunity. Mol Med 12, 334-341 (2006). 
39. Malavasi, F., et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene 
family in physiology and pathology. Physiol Rev 88, 841-886 (2008). 
40. Johnson, J.D., et al. Suppressed insulin signaling and increased apoptosis in CD38-
null islets. Diabetes 55, 2737-2746 (2006). 
41. Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. Transcriptional silencing 
and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 
795-800 (2000). 
42. Haigis, M.C., et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects 
of calorie restriction in pancreatic beta cells. Cell 126, 941-954 (2006). 
43. Schwer, B., et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and 
causes obesity. Proc Natl Acad Sci U S A 107, 21790-21794 (2010). 
44. Klar, A.J., Fogel, S. & Macleod, K. MAR1-a Regulator of the HMa and HMalpha 
Loci in SACCHAROMYCES CEREVISIAE. Genetics 93, 37-50 (1979). 
45. Smith, J.S. & Boeke, J.D. An unusual form of transcriptional silencing in yeast 
ribosomal DNA. Genes Dev 11, 241-254 (1997). 
46. Gottlieb, S. & Esposito, R.E. A new role for a yeast transcriptional silencer gene, 
SIR2, in regulation of recombination in ribosomal DNA. Cell 56, 771-776 (1989). 
47. Bryk, M., et al. Transcriptional silencing of Ty1 elements in the RDN1 locus of 
yeast. Genes Dev 11, 255-269 (1997). 
48. Sinclair, D.A. & Guarente, L. Extrachromosomal rDNA circles--a cause of aging in 
yeast. Cell 91, 1033-1042 (1997). 
  26 
49. Tissenbaum, H.A. & Guarente, L. Increased dosage of a sir-2 gene extends lifespan 
in Caenorhabditis elegans. Nature 410, 227-230 (2001). 
50. Viswanathan, M. & Guarente, L. Regulation of Caenorhabditis elegans lifespan by 
sir-2.1 transgenes. Nature 477, E1-2 (2011). 
51. Rogina, B. & Helfand, S.L. Sir2 mediates longevity in the fly through a pathway 
related to calorie restriction. Proc Natl Acad Sci U S A 101, 15998-16003 (2004). 
52. Houtkooper, R.H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and 
healthspan. Nat Rev Mol Cell Biol 13, 225-238 (2012). 
53. Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K. & Horio, Y. Nucleocytoplasmic 
shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem 282, 
6823-6832 (2007). 
54. Moynihan, K.A., et al. Increased dosage of mammalian Sir2 in pancreatic beta cells 
enhances glucose-stimulated insulin secretion in mice. Cell Metab 2, 105-117 (2005). 
55. Chen, I.Y., et al. Histone H2A.z is essential for cardiac myocyte hypertrophy but 
opposed by silent information regulator 2alpha. J Biol Chem 281, 19369-19377 
(2006). 
56. Rosenberg, M.I. & Parkhurst, S.M. Drosophila Sir2 is required for heterochromatic 
silencing and by euchromatic Hairy/E(Spl) bHLH repressors in segmentation and sex 
determination. Cell 109, 447-458 (2002). 
57. Vaziri, H., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. 
Cell 107, 149-159 (2001). 
58. Luo, J., et al. Negative control of p53 by Sir2alpha promotes cell survival under 
stress. Cell 107, 137-148 (2001). 
  27 
59. Rodgers, J.T., et al. Nutrient control of glucose homeostasis through a complex of 
PGC-1alpha and SIRT1. Nature 434, 113-118 (2005). 
60. Lagouge, M., et al. Resveratrol improves mitochondrial function and protects against 
metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122 (2006). 
61. Gerhart-Hines, Z., et al. Metabolic control of muscle mitochondrial function and 
fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 26, 1913-1923 (2007). 
62. Daitoku, H., et al. Silent information regulator 2 potentiates Foxo1-mediated 
transcription through its deacetylase activity. Proc Natl Acad Sci U S A 101, 10042-
10047 (2004). 
63. Rodgers, J.T. & Puigserver, P. Fasting-dependent glucose and lipid metabolic 
response through hepatic sirtuin 1. Proc Natl Acad Sci U S A 104, 12861-12866 
(2007). 
64. Nie, Y., et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat 
Cell Biol 11, 492-500 (2009). 
65. Ponugoti, B., et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation 
of hepatic lipid metabolism. J Biol Chem 285, 33959-33970 (2010). 
66. Walker, A.K., et al. Conserved role of SIRT1 orthologs in fasting-dependent 
inhibition of the lipid/cholesterol regulator SREBP. Genes Dev 24, 1403-1417 
(2010). 
67. Li, X., et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. 
Mol Cell 28, 91-106 (2007). 
  28 
68. Kemper, J.K., et al. FXR acetylation is normally dynamically regulated by p300 and 
SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 10, 392-
404 (2009). 
69. Picard, F., et al. Sirt1 promotes fat mobilization in white adipocytes by repressing 
PPAR-gamma. Nature 429, 771-776 (2004). 
70. Bordone, L., et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic 
beta cells. PLoS Biol 4, e31 (2006). 
71. Kitamura, Y.I., et al. FoxO1 protects against pancreatic beta cell failure through 
NeuroD and MafA induction. Cell Metab 2, 153-163 (2005). 
72. Cakir, I., et al. Hypothalamic Sirt1 regulates food intake in a rodent model system. 
PLoS One 4, e8322 (2009). 
73. Satoh, A., et al. SIRT1 promotes the central adaptive response to diet restriction 
through activation of the dorsomedial and lateral nuclei of the hypothalamus. J 
Neurosci 30, 10220-10232 (2010). 
74. Ramadori, G., et al. SIRT1 deacetylase in POMC neurons is required for homeostatic 
defenses against diet-induced obesity. Cell Metab 12, 78-87 (2010). 
75. Ramadori, G., et al. SIRT1 deacetylase in SF1 neurons protects against metabolic 
imbalance. Cell Metab 14, 301-312 (2011). 
76. North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M. & Verdin, E. The human Sir2 
ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11, 437-444 
(2003). 
  29 
77. Beirowski, B., et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination 
through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl 
Acad Sci U S A 108, E952-961 (2011). 
78. Jiang, W., et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 
degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell 43, 33-44 (2011). 
79. Jing, E., Gesta, S. & Kahn, C.R. SIRT2 regulates adipocyte differentiation through 
FoxO1 acetylation/deacetylation. Cell Metab 6, 105-114 (2007). 
80. Hirschey, M.D., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by 
reversible enzyme deacetylation. Nature 464, 121-125 (2010). 
81. Shimazu, T., et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl 
CoA synthase 2 and regulates ketone body production. Cell Metab 12, 654-661 
(2010). 
82. Hallows, W.C., Lee, S. & Denu, J.M. Sirtuins deacetylate and activate mammalian 
acetyl-CoA synthetases. Proc Natl Acad Sci U S A 103, 10230-10235 (2006). 
83. Schwer, B., Bunkenborg, J., Verdin, R.O., Andersen, J.S. & Verdin, E. Reversible 
lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA 
synthetase 2. Proc Natl Acad Sci U S A 103, 10224-10229 (2006). 
84. Hallows, W.C., et al. Sirt3 promotes the urea cycle and fatty acid oxidation during 
dietary restriction. Mol Cell 41, 139-149 (2011). 
85. Qiu, X., Brown, K., Hirschey, M.D., Verdin, E. & Chen, D. Calorie restriction 
reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12, 662-
667 (2010). 
  30 
86. Someya, S., et al. Sirt3 mediates reduction of oxidative damage and prevention of 
age-related hearing loss under caloric restriction. Cell 143, 802-812 (2010). 
87. Nasrin, N., et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene 
expression in liver and muscle cells. J Biol Chem 285, 31995-32002 (2010). 
88. Nakagawa, T., Lomb, D.J., Haigis, M.C. & Guarente, L. SIRT5 Deacetylates 
carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137, 560-570 
(2009). 
89. Michishita, E., et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates 
telomeric chromatin. Nature 452, 492-496 (2008). 
90. Kawahara, T.L., et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-
dependent gene expression and organismal life span. Cell 136, 62-74 (2009). 
91. Zhong, L., et al. The histone deacetylase Sirt6 regulates glucose homeostasis via 
Hif1alpha. Cell 140, 280-293 (2010). 
92. Ford, E., et al. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I 
transcription. Genes Dev 20, 1075-1080 (2006). 
93. Vakhrusheva, O., et al. Sirt7 increases stress resistance of cardiomyocytes and 















Nicotinamide mononucleotide,  
a key NAD+ precursor, 
treats the pathophysiology of 










Type 2 diabetes (T2D) has become an epidemic in our modern lifestyle, likely due to 
calorie-rich diets overwhelming our adaptive metabolic pathways.  One such pathway is 
mediated by nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme 
in mammalian NAD+ biosynthesis, and the NAD+-dependent protein deacetylase SIRT1.  
Here we show that NAMPT-mediated NAD+ biosynthesis is severely compromised in 
metabolic organs by high-fat diet (HFD).  Strikingly, nicotinamide mononucleotide 
(NMN), a product of the NAMPT reaction and a key NAD+ intermediate, ameliorates 
glucose intolerance by restoring NAD+ levels in HFD-induced T2D mice.  NMN also 
enhances hepatic insulin sensitivity and restores gene expression related to oxidative 
stress, inflammatory response, and circadian rhythm, partly through SIRT1 activation.  
Furthermore, NAD+ and NAMPT levels show significant decreases in multiple organs 
during aging, and NMN improves glucose intolerance and lipid profiles in age-induced 
T2D mice.  These findings provide critical insights into a novel intervention against diet- 






Recent studies have raised an interesting possibility that various physiological 
mechanisms that mediate metabolic adaptation have evolved in response to nutritionally 
scarce conditions such as famine and drought (Lazar, 2005).  In our modern, sedentary 
lifestyle with calorie-rich diets, such adaptive mechanisms could be seriously 
overwhelmed, causing an epidemic of obesity and T2D worldwide (Yach et al., 2006).  In 
mammals, one such mechanism comprises NAMPT-mediated NAD+ biosynthesis and the 
NAD+-dependent protein deacetylase SIRT1 (Haigis and Sinclair, 2010; Houtkooper et 
al., 2010; Imai, 2010; Imai and Guarente, 2010).  NAMPT-mediated NAD+ biosynthesis 
and SIRT1 together play critical roles in regulating a variety of biological processes that 
include metabolism, stress response, cellular differentiation, and circadian rhythm, and 
also mediating adaptive responses to limited energy intake, such as fasting and diet 
restriction (Imai, 2010).  For example, in skeletal muscle, both nutritional deprivation and 
exercise increase Nampt expression through the activation of AMP-activated protein 
kinase (AMPK), enhancing NAD+ biosynthesis and SIRT1 activity (Canto et al., 2010; 
Costford et al., 2010; Fulco et al., 2008).  In pancreatic b cells, both NAMPT-mediated 
NAD+ biosynthesis and SIRT1 regulate glucose-stimulated insulin secretion (GSIS) in 
response to glucose availability (Moynihan et al., 2005; Revollo et al., 2007).  
Additionally, in the liver and white adipose tissue (WAT), NAMPT and SIRT1 comprise a 
novel transcriptional-enzymatic feedback loop for the regulation of circadian rhythm, a 
powerful effecter for metabolism (Nakahata et al., 2009; Ramsey et al., 2009). 
How nutritional and environmental perturbations affect the system dynamics of 
this NAMPT/NAD+/SIRT1-driven adaptive, systemic regulatory network, named the 
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“NAD World” (Imai, 2010), still remains unclear.  Here we show that HFD and aging 
compromise NAMPT-mediated NAD+ biosynthesis, contributing to the pathogenesis of 
T2D.  Importantly, we also provide evidence that promoting NAD+ biosynthesis by using 
nicotinamide mononucleotide (NMN), a product of the NAMPT reaction and a key 




To examine the connection between NAMPT-mediated NAD+ biosynthesis and T2D, 
wild-type B6 male and female mice at 3-6 months of age were fed a HFD containing 42% 
calories from fat.  Both males and females developed overt diabetes after 3.5 and 6 
months, respectively.  In these mice, we found that NAMPT protein levels were 
significantly reduced in the liver and WAT, but not in skeletal muscle, compared to 
regular chow (RC)-fed control mice (Figures 1A, S1A, and S1B).  Consistent with these 
decreases in NAMPT levels, NAD+ levels were also significantly reduced in the liver and 
WAT, but not in skeletal muscle (Figures 1B and S1C), indicating that there is an 
underlying defect in NAD+ biosynthesis in the liver and WAT of HFD-induced diabetic 
mice. 
Based on these findings, we hypothesized that the defect in NAMPT-mediated 
NAD+ biosynthesis could be ameliorated by administering NMN to diabetic mice.  To 
test this idea, we initially examined how NMN administration influences NAD+ 
biosynthesis in the liver, pancreas, and WAT.  NMN was immediately utilized and 
converted to NAD+ within 15 min, resulting in significant increases in NAD+ levels over 
60 min (Figures 1C and S1D).  We also observed a mild increase (~5-fold) in 
nicotinamide riboside (NR) levels compared to the ~15-fold increase of NMN, implying 
that a part of NMN might be converted to NR to get into the liver (Figure S1E).  We 
further confirmed that NMN enhanced NAD+ biosynthesis in mouse primary hepatocytes 
in a dose-dependent manner (Figure 1D).  NMN was also able to overcome NAD+ 
deficits caused by a potent NAMPT inhibitor FK866 (Hasmann and Schemainda, 2003) 
but unable to alleviate the NAD+ reduction due to the inhibition of nicotinamide/nicotinic 
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acid mononucleotide adenylyltransferases (NMNATs) by their potent inhibitor 
gallotannin (Berger et al., 2005) (Figures 1E and S1F).  These results demonstrate the 
effectiveness and specificity of NMN at stimulating NAD+ biosynthesis in vivo and in 
vitro. 
Given these findings, we administered NMN at a dose of 500 mg/kg body 
weight/day intraperitoneally to HFD-fed male and female diabetic mice for 10 and 7 
consecutive days, respectively.  No overt abnormalities or changes in body weight were 
detected during this time (data not shown).  NMN administration successfully restored 
NAD+ levels in the liver and WAT of diabetic mice, and even in diabetic skeletal muscle, 
a moderate but significant increase in NAD+ was detected (Figure 1B).  These results 
demonstrate the efficacy of NMN treatment in ameliorating the underlying defect in 
NAD+ biosynthesis in HFD-induced diabetes. 
Strikingly, NMN administration completely normalized impaired glucose 
tolerance in diabetic female mice (Figure 2A).  Whereas plasma insulin levels during 
intraperitoneal glucose tolerance tests (IPGTTs) did not differ before and after NMN 
treatment, insulin tolerance was significantly improved in these females (Figures 2B and 
2C).  In diabetic males, NMN did improve impaired glucose tolerance, but the effect was 
milder compared to the females (Figure 2D).  Different from females, GSIS in males was 
enhanced at 15- and 30-min time points in IPGTTs after NMN administration (Figure 
2E).  Using primary pancreatic islets isolated from diabetic males, we also confirmed that 
both NAD+ levels and GSIS were enhanced by NMN (Figure S2).  On the other hand, 
insulin tolerance remained unchanged in males (Figures 2F), suggesting that NMN exerts 
its major effects on different target tissues between males and females.  Although the 
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reason for this sex difference is currently unclear, these results demonstrate that NMN 
treatment can ameliorate impaired glucose tolerance by improving either insulin 
sensitivity or insulin secretion in HFD-induced diabetic mice. 
Given that NMN administration restored normal NAD+ levels in diabetic livers 
(Figure 1B) and also that the liver is known to have a major effect on insulin sensitivity 
in mice (Home and Pacini, 2008), we examined whether NMN improves hepatic insulin 
sensitivity in diabetic females.  We first assessed phosphorylation status of AKT, a 
downstream kinase in insulin signaling, in diabetic livers with or without NMN 
treatment.  Clear increases in AKT phosphorylation were detected in NMN-treated 
diabetic mice, indicating that hepatic insulin sensitivity is improved by NMN treatment 
(Figure 3A).  We next compared gene expression profiles between RC-fed, HFD-fed, and 
NMN-treated HFD-fed livers.  We also performed the parametric analysis of gene set 
enrichment (PAGE) (Kim and Volsky, 2005) using these gene expression data and GO 
gene sets.  Interestingly, the biological pathways and genes related to oxidative stress, 
inflammatory response, immune response, and lipid metabolism, all of which are known 
to contribute to hepatic insulin resistance (Mattson, 2009; Shoelson et al., 2006), were 
affected by HFD and reversed by NMN (Figures 3B and S3A).  For example, pathways 
related to glutathione S-transferases, which play an important role in the protection from 
lipid peroxidation products and thereby the maintenance of hepatic insulin sensitivity 
(Mattson, 2009), were suppressed by HFD and restored by NMN (Figure 3B, 
GO:0004364 and GO: 0016765).  Indeed, expression levels of the glutathione S-
transferase alpha 2 gene (Gsta2) were significantly reduced by HFD and recovered by 
NMN (Figures 3C).  Gsta1 and Gsta4 also showed the same directions of changes (12.3 
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and 6.18 for the sum of Z ratio, respectively), although their false discovery rates did not 
reach statistical significance (data not shown).  Pathways related to damage, 
inflammatory, and immune responses were induced by HFD and suppressed by NMN 
(Figure 3B, GO:0006952, GO:0006954, GO:0009611, GO:0006955, and GO:0009605).  
Consistent with these pathway alterations, expression levels of the interleukin 1b gene 
(Il1b) and the S100 calcium binding protein A8 and A9 genes (S100a8 and S100a9), 
which are all direct NF-kB target genes and play important roles in hepatic insulin 
resistance (Nemeth et al., 2009; Nov et al., 2010), were significantly up-regulated by 
HFD and down-regulated by NMN (Figures 3C and S3A).  Other genes that showed 
significant changes by both HFD and NMN, such as Lipin1 (Croce et al., 2007) and 
pyruvate dehydrogenase kinase 4 (Pdk4) (Jeoung and Harris, 2008), have also been 
connected to insulin resistance.  It should also be noted that expression of genes related to 
circadian rhythm (Dbp, Dec1, and Rev-erb-a) were altered by HFD and reversed by 
NMN (Figures 3C).  The genes regulated by DBP, such as Cyp2a5 and Rgs16, also 
showed similar expression profiles (Figure 3C and S3A).  These findings provide strong 
support for the importance of NAMPT-mediated NAD+ biosynthesis in the connection 
between circadian rhythm and metabolic disorders (Ramsey et al., 2009). 
To elucidate what transcription factors mediate expression changes by HFD and 
NMN, biological network analysis was performed using the shortest path and the 
transcription regulation (TR) algorithms (Figure S3B).  We noticed that transcription 
factors that formed relatively large hubs in the deduced network, such as c-Myc, NF-kB, 
PPARγ, and p53, are all reported targets of SIRT1 (Figure S3C), implying that SIRT1 
might be one of the mediators for the observed gene expression changes.  Given that NF-
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kB is regulated by SIRT1-mediated deacetylation (Yeung et al., 2004) and plays a critical 
role in hepatic insulin resistance (Shoelson et al., 2006), we analyzed acetylation status of 
NF-kB in livers from each experimental condition (Figure 3D).  Consistent with changes 
in NAD+ levels and NF-kB target gene expression, levels of acetylated p65, a component 
of NF-kB, increased by HFD and decreased considerably by NMN, suggesting that 
SIRT1 activity is suppressed by HFD and restored by NMN. 
Because both inflammatory cytokines and oxidative stress are linked to hepatic 
insulin resistance (Evans et al., 2005; Peraldi and Spiegelman, 1998), we also tested 
whether TNF-a and menadione can affect NAMPT-mediated NAD+ biosynthesis and 
cause similar gene expression changes in vitro.  Interestingly, whereas both reagents were 
able to significantly reduce NAMPT and NAD+ levels in primary hepatocytes, only TNF-
a showed gene expression patterns similar to those in HFD-fed diabetic livers (Figure 3E, 
3F, S3D, and data not shown).  This TNF-a-mediated decrease in NAD+ levels was 
ameliorated by NMN (Figure 3F).  In TNF-a/NMN-treated primary hepatocytes, NMN 
was able to restore the Gsta2 expression to a similar level observed in HFD-fed, NMN-
treated livers, and its effect was abrogated by EX527, a potent SIRT1-specific inhibitor, 
further confirming that SIRT1 is at least one of the mediators for the effect of NMN 
(Figure 3G). 
In addition to calorie-rich diets, aging is one of the greatest risk factors for 
developing T2D (Moller et al., 2003).  We found that NAD+ levels showed significant 
decreases in the pancreas, WAT, and skeletal muscle and also the same trend with a much 
larger variation in the liver in old mice, compared to those in young mice (Figure 4A).  
NAMPT protein levels also decreased in those tissues (Figures S4A and S4B).  Based on 
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these findings, we speculated that NMN treatment might also be effective in age-induced 
T2D models.  We screened RC wild-type B6 males and females at 15-26 months of age 
and found ~15% of males diabetic (>200 mg/dl at 2-hr time point in IPGTTs).  To these 
aged, naturally occurring diabetic male mice, we intraperitoneally administered the same 
dose of NMN.  Surprisingly, just one dose of NMN normalized impaired glucose 
tolerance (Figure 4B).  In these mice, GSIS at 15- and 30-min time points during IPGTTs 
were higher after NMN treatment, although the difference did not reach statistical 
significance (Figure 4C).  This is consistent with the results in HFD-induced diabetic 
male mice (Figure 2E).  Importantly, NMN did not convey any significant effects to aged 
non-diabetic male mice (Figures S4C and S4D), indicating that NMN treatment is 
effective for age-induced diabetic individuals and does not negatively affect glucose 
homeostasis in non-diabetic individuals.  Because females proved difficult to naturally 
develop T2D, we fed aged female mice a HFD for 7 weeks.  Unlike younger females, 
aged females were very susceptible to HFD and developed severe diabetes within this 
time frame.  In these aged, diabetic females, 11 consecutive injections of NMN 
completely normalized severely impaired glucose tolerance (Figure 4D).  Qualitatively 
consistent with this improvement, their respiratory quotient (RQ) showed a significant 
increase after NMN treatment, implicating better glucose utilization, although their 
oxygen consumption did not change (Figure S4E).  Rectal body temperature also 
decreased, which might be explained by a significant shift in energy utilization from fat 
to glucose (Figure S4F).  Furthermore, hyperlipidemia induced by HFD was also 
corrected by NMN (Figure 4E).  Thus, these results support the efficacy of NMN to 





The results presented in this study demonstrate that NAMPT-mediated NAD+ 
biosynthesis is compromised by HFD and aging, contributing to the pathogenesis of T2D. 
We also provide proof of the concept that promoting NAD+ biosynthesis by administering 
NMN, a key NAD+ intermediate, can be an effective intervention to treat the 
pathophysiology of diet- and age-induced T2D (Figure S4G).  In both diabetic models, 
NMN administration dramatically ameliorated impaired glucose tolerance by restoring 
normal NAD+ levels and enhancing either insulin sensitivity or insulin secretion, 
supporting our conclusion that underlying defects in NAMPT-mediated NAD+ 
biosynthesis play an important role in the pathogenesis of diet- and age-induced T2D.  
Although the short-term NMN administration was unable to achieve a significant 
improvement of fasted glucose levels, NMN is still effective at normalizing multiple 
metabolic pathways, such as oxidative stress, inflammatory response and circadian 
rhythm, and GSIS, in T2D.  Whereas how NMN is transported into cells currently 
remains unknown, metabolic tissues and organs seem to utilize NMN and convert it to 
NAD+ efficiently.  Therefore, an adequate and consistent supply of this key NAD+ 
intermediate must be critical to maintain normal hepatic insulin sensitivity and GSIS in 
pancreatic b cells.  To assess beneficial and possible adverse effects of NMN more 
comprehensively, we are currently conducting long-term NMN supplementation 
experiments in different dietary conditions. 
 Inflammation and/or oxidative stress caused by hepatosteatosis or aging appear to 
trigger the reduction in NAMPT-mediated NAD+ biosynthesis and contribute to the 
pathogenesis of T2D.  Given that NMN is capable of reversing changes in gene 
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expression related to oxidative stress, inflammatory response, and circadian rhythm, 
NAMPT-mediated NAD+ biosynthesis regulates homeostatic, protective mechanisms 
against nutritional perturbations, such as HFD.  Our results also indicate that SIRT1 is at 
least one of the mediators for these beneficial effects of NMN on hepatic insulin 
sensitivity.  In addition to SIRT1, there might be other NAD+-sensitive or NAD+-
consuming factors that also contribute to the effects of NMN.  For example, other sirtuin 
family members (SIRT2-7) also likely play some roles in the metabolic effects of NMN.  
Particularly, the functions of mitochondrial sirtuins (SIRT3-5) might be affected by 
deficits in NAMPT-mediated NAD+ biosynthesis, potentially resulting in the 
mitochondrial dysfunction observed in T2D (Lowell and Shulman, 2005).  The sex 
difference that we observed in this study is also interesting.  Given that estrogen signaling 
is critical for the regulation of hepatic insulin sensitivity and GSIS (Meyer et al., 2011), 
estrogen might play a role in the effects of NMN under HFD feeding.  Further 
investigation will be required to identify detailed mechanisms for the efficacy of NMN. 
 Our results provide an interesting implication that NMN supplementation might 
also be effective in human T2D patients if they have defects in NAMPT-mediated NAD+ 
biosynthesis.  Because NMN is an endogenous compound, this is rather a nutriceutical 
approach to T2D.  Nonetheless, it will be of great interest to examine whether the effects 
of NMN are synergistic with those of small chemical SIRT1 activators (Milne et al., 
2007), particularly in aged, diabetic individuals.  Taken together, we anticipate that long-
term NMN administration might be a highly effective way to sustain enhanced SIRT1 
activity in tissues and organs where NAMPT-mediated NAD+ biosynthesis is 




For the HFD-induced T2D model, mice at 3-6 months of age were fed a HFD containing 
42% of the total calories from fat (TD88137; Harlan Taklad).  We defined diabetes as 
mice having fasted blood glucose levels > 120 mg/dl or blood glucose levels at 2-hr time 
point in IPGTTs ≥ 200 mg/dl.  To obtain age-induced diabetic mice, we screened male 
and female mice at 15-26 months of age following the criteria.  For NMN treatment, we 
intraperitoneally administered NMN (Sigma) at the dose of 500 mg/kg body weight/day 
as indicated in the text and figure legends.  This dose was determined in our previous 
studies (Revollo et al., 2007; Ramsey et al., 2008).  All animal studies were approved by 
the Washington University Animal Studies Committee.  Details are available in the 
Supplemental Experimental Procedure. 
 
NAD+ and NMN measurements 
NAD+ and NMN levels were determined using a HPLC system (Shimadzu) with a 
Supelco LC-18-T column (15cm x 4.6cm; Sigma) and a Hypercarb column (15cm x 
4.6cm; Thermo Scientific), respectively.  Details are available in the Supplemental 
Experimental Procedure. 
 
Primary hepatocyte isolation 
Primary hepatocytes were isolated from mice by hepatic portal collagenase perfusion and 
cultured in DMEM as described previously (Grimm et al., 2011).  For treatments with 
NMN, enzyme inhibitors (FK866, gallotannin, EX527), TNF-a, and menadione, 
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hepatocytes were cultured in DMEM containing 1.0% FBS and each reagent or their 
combinations as indicated in the text. 
 
Micoroarrays 
Total RNA was isolated from frozen liver samples of RC, HFD, and NMN-treated HFD 
mice and used for Illumina Mouse Ref 8 whole genome microarrays (version 2).  Details 
are available in the Supplemental Experimental Procedure.   
 
Quantitative Real-Time PCR 
Real-time PCR was performed using the 7900HT Fast Real-Time PCR System (Applied 
Biosystems).  Relative expression levels were determined based on the CT values and 
normalized to CT values for the Gapdh gene.  P values for the differences of CT values 
were calculated using one-way ANOVA with the Fisher's PLSD test. 
 
Detection of acetylated NF-kB p65 
Nuclear extracts were prepared from frozen liver samples as previously described 
(Rodgers and Puigserver, 2007).  100 mg of liver nuclear extract were analyzed by 
Western blotting with an anti-acetyl NF-?B p65 (Lys310) antibody (Cell Signaling 
Technology).  The same blot was re-probed with anti-NF-kB p65 antibody (Santa Cruz).  
Signals were visualized using the ECL Plus detection system (Amersham). 
 
Statistical Analyses 
Differences between two groups were assessed using Student's paired or unpaired t test.  
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Comparisons among several groups were performed using one-way ANOVA with the 





Figure 1.  NMN ameliorates defects in NAMPT-mediated NAD+ biosynthesis in 
HFD-induced diabetic mice.  (A) NAMPT protein levels in the liver, WAT, and skeletal 
muscle.  Female mice were fed a RC or a HFD for 6-8 months.  NAMPT levels were 
normalized to ACTIN (liver) or TUBULIN (WAT and skeletal muscle)  (n=4 to 5 mice 
per group).  (B) Tissue NAD+ levels in the liver, WAT, and skeletal muscle from RC, 
HFD, and NMN-treated HFD mice (n=5 to 13 mice per group).  NMN (500mg/kg body 
weight/day) was given intraperitoneally to HFD-fed female mice for 7 consecutive days.  
(C) Changes in NMN and NAD+ levels in the liver after administering a single dose of 
NMN to B6 mice (n=3 to 5 mice for each time point).  (D and E) Intracellular NAD+ 
levels in mouse primary hepatocytes.  Cells were treated with NMN at the indicated 
concentrations (D), or with enzyme inhibitors [500 nM FK866 or 100 mM gallotannin 
(GTN)] in the presence or absence of 100 mM NMN (E), for 4 hrs (n=3 per group).  Data 
were analyzed by Student’s unpaired t test (A) and one-way ANOVA with the Fisher's 
PLSD post-hoc test (B, D, E).  All values are presented as mean ± SEM.  *P < 0.05; **P 
<0.01; ***P < 0.001. 
 
Figure 2.  NMN administration improves impaired glucose tolerance in HFD-
induced diabetic mice.   (A and D) Glucose tolerance in HFD female (A) and male mice 
(D) before and after NMN treatment (n=10 for females, and n=6 for males).  IPGTTs 
were conducted with the same individuals before (closed circles) and after (open circles) 
NMN.  NMN (500mg/kg body weight/day) was administered to female and male mice 
for 7 and 10 consecutive days, respectively.  The areas under each glucose tolerance 
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curve are presented next to the glucose tolerance curves.  (B and E) Plasma insulin levels 
in female (B) and male (E) mice during IPGTTs before and after NMN treatment (n=10 
for females, and n=6 for males).   (C and F) Insulin tolerance in HFD female (C) and 
male (F) mice before and after NMN treatment (n=10 for females, and n=6 for males).  
ITTs were performed before (closed circles) and after (open circles) NMN.  ITTs were 
conducted several days before or after IPGTTs.  The areas under each insulin tolerance 
curve are presented next to the insulin tolerance curves.  Data were analyzed by Student’s 
paired t test.  All values are presented as mean ± SEM.  *P < 0.05; **P <0.01; ***P < 
0.001. 
 
Figure 3.  NMN ameliorates hepatic insulin resistance and restores gene expression 
related to oxidative stress, inflammatory response, and circadian rhythm.  (A) The 
phosphorylation status of AKT in HFD and NMN-treated HFD female livers (n=3 mice 
per group).  Signal levels of phosphorylated AKT were normalized to total AKT protein 
levels.  (B) Biological pathways that were altered by HFD and reversed by NMN in 
female livers.  Parametric analysis of gene-set enrichment (PAGE) was performed to 
identify pathways that were significantly up-regulated (red) or down-regulated (blue) by 
either HFD or NMN using our microarray data (n=4 mice for each condition).  Twenty 
top pathways are listed following the sum of the absolute values of Z scores between two 
comparisons.  (C) Quantitative RT-PCR results for representative genes related to 
oxidative stress, inflammatory response, circadian rhythm, and metabolism (n=4 to 5 
mice per group).  Gsta2, glutathione S-transferase alpha 2; Il1b, interleukin 1 beta; Pdk4, 
pyruvate dehydrogenase kinase isozyme 4; Dbp, D site of albumin promoter (albumin D-
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box) binding protein; Dec1, deleted in esophageal cancer 1.  (D) Acetylation status of 
NF-kB p65 in RC, HFD, and NMN-treated HFD livers.  Two independent sets of mice 
were used for this analysis, and numbers below each panel represent normalized ratios of 
acetylated to total p65 levels.  (E-G) The effects of TNF-a on NAMPT-mediated NAD+ 
biosynthesis and gene expression in mouse primary hepatocytes.  Cells were treated with 
50 ng/ml TNF-a for 72 hrs and given indicated reagents for 6 hrs prior to harvesting for 
measurements.  (E) NAMPT protein levels were normalized to ACTIN (n=3 per group).  
(F) TNF-a-treated cells were given 100 mM NMN prior to NAD+ measurements (n=3-6 
per group).  (G) TNF-a-treated cells were cultured with NMN or NMN plus 40 mM 
EX527 and examined for Gsta2 expression (n=6-9 per group).  Data were analyzed by 
Student’s unpaired t test (A, E).  Differences in Ct values or NAD+ levels were analyzed 
with one-way ANOVA with the Fisher’s PLSD post-hoc test (D, F, G).  All values are 
presented as mean ± SEM.  *P < 0.05; **P <0.01; ***P < 0.001.  
 
Figure 4.  NMN improves glucose and lipid homeostasis in age-induced T2D. (A) 
NAD+ levels in metabolic tissues between young and old mice.  Pancreas, liver, WAT, 
and skeletal muscle were collected from young (n=5-11) and old (n=5-15) mice at 3-6 
and 25-31 months of age, respectively.  (B) Glucose tolerance in aged, naturally 
occurring diabetic male mice before (closed circles) and after (open circles) a single dose 
of NMN (500 mg/kg body weight) (n=11).  The areas under each glucose tolerance curve 
are presented next to the glucose tolerance curves.  (C) Plasma insulin levels were 
measured during IPGTTs (n=5).  (D and E) Glucose tolerance (D) and lipid levels (E) in 
aged HFD female mice before (closed circles) and after (open circles) NMN (n=5).  
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Fasted plasma samples were collected from the same mice and subjected to the 
measurements of cholesterol (Chol), triglycerides (TG), and non-esterified free fatty acids 
(FFA).  Data were analyzed by Student’s unpaired t test (A), paired t test (B-D), and one-
way ANOVA with the Fisher's PLSD post-hoc test (E).  All values are presented as mean 
± SEM.  *P < 0.05; **P <0.01; ***P < 0.001. 
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Figure S1.  Defects in NAMPT-mediated NAD+ biosynthesis in high-fat diet-induced 
diabetic mice.  (A) Western blots of NAMPT in the liver, white adipose tissue (WAT), 
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and skeletal muscle in RC and HFD female mice.  (B and C) Levels of NAMPT (B) and 
NAD+ (C) in the liver, WAT, and skeletal muscle were measured in RC and HFD male 
mice.  Mice at 3-6 months of age were fed a RC or a HFD for at least 3.5 months.  
NAMPT protein levels in RC and HFD mice were normalized to ACTIN (liver and WAT) 
or TUBULIN (skeletal muscle) (n=3-5 mice per group).  NAD+ levels were measured by 
HPLC (n=4-9 mice per group).  (D) Changes in NMN and NAD+ levels in the pancreas 
and WAT after NMN administration (500mg/kg body weight) (n=3 to 6 mice for each 
time point).  (E) Relative nicotinamide riboside (NR) levels in liver extracts prepared 
from NMN-administered B6 female mice.  Relative levels were assessed by the selected 
reaction monitoring (SRM) mode in LC/MS/MS (n=3 mice for each time point).  (F) A 
diagram of the NAMPT-mediated NAD+ biosynthetic pathway.  Nicotinamide (Nic) is the 
major precursor for NAD+ biosynthesis in mammals.  NAMPT catalyzes the conversion 
of Nic to NMN as the rate-limiting enzyme in this pathway.  Nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase (NMNAT) converts NMN into NAD+.  Enzyme 
inhibitors (FK866 and gallotannin) of the pathway are indicated.   Data were analyzed by 









Figure S2.  NAD+ levels and glucose-stimulated insulin secretion in HFD-fed 
primary islets treated with NMN.  Primary islets isolated from HFD male mice were 
incubated in the presence or absence of 100 µM NMN for 24 hrs prior to NAD+ 
measurement (A, n=6 islet groups from 4-6 mice) or glucose stimulation (B, n=18 islet 
groups from 8-12 mice).  Data were analyzed by Student’s unpaired t test.  All values are 







Figure S3.  Microarray analysis of liver samples from RC, HFD, and NMN-treated 
HFD mice.  (A) Gene expression data from microarrays were subjected to Z score 
transformation, and Z ratios were calculated.  Genes were filtered based on false 
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discovery rates calculated by the Rank Product Analysis for the differences in expression 
levels between two conditions (RC vs HFD [HFD:RC] or HFD vs NMN-treated HFD 
[NMN:HFD]).  Genes that showed their false discovery rates (FDR) less than 5% were 
selected and ordered based on the sum of the absolute numbers of Z ratios, a parameter 
that reflects the extent of the alterations between HFD feeding and NMN treatment.  (B) 
The network was generated using the shortest path algorithm in the MetaCore program 
(GeneGo).  (C) The transcription regulation (TR) algorithm was applied to identify 
transcription factors that likely cause gene expression changes detected by our microarray 
analyses.  The total numbers of nodes were determined, and the probabilities of those 
links represented by zScore and gScore, and their p-values were calculated based on 
hypergeometric distribution.  The resultant transcription factors were ranked by p-values.  
Transcription factors showing large total numbers of nodes (red) are all SIRT1 targets. 
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(D) The effects of menadione, an oxidative stress-inducing reagent, on NAMPT protein 
and NAD+ levels.  Primary hepatocytes were treated with 20 µM menadione (MND) for 5 
hrs.  Data were analyzed by Student’s unpaired t test.  All values are presented as mean ± 
SEM.  *P < 0.05; **P <0.01. 
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Figure S4.  NAMPT protein levels and the effect of NMN on metabolism in aged 
mice.  (A and B) Western blots of NAMPT in the liver, WAT, and skeletal muscle 
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between young and old mice.  NAMPT protein levels were normalized to ACTIN (liver 
and skeletal muscle) or TUBULIN (WAT)  (B, n= 3-4 mice per group).  (C) Glucose 
tolerance in aged, non-diabetic male mice before (closed circles) and after (open circles) 
a single dose of NMN (n=7).  The areas under each glucose tolerance curve are presented 
next to the glucose tolerance curves.  (D) Plasma insulin levels were measured during 
IPGTTs for non-diabetic mice (n=6-7).  (E and F) Indirect calorimetry over a 12-hr 
period (7:00 pm-7:00 am) and body temperature in HFD females.  Female mice at 10-11 
months of age were fed HFD for 8 weeks and treated with NMN.  Oxygen consumption 
(VO2), respiratory quotient (RQ) (E, n=3 independent measurements, 2 mice per 
measurement), and rectal body temperature (F, n=6 per group) were measured before and 
after NMN.  Data were analyzed by Student’s paired or unpaired t test.  All values are 
presented as mean ± SEM.  *P < 0.05; **P <0.01.  (G) A model for the effect of NMN 
against diet- and age-induced T2D.  NAMPT-mediated NAD+ biosynthesis is 
compromised by HFD or aging, contributing to the pathogenesis of T2D.  NMN restores 







SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Animal Experimentation 
Wild-type C57BL/6J mice were bred in our laboratory or purchased from Jackson 
Laboratories.  Mice were maintained on a regular chow (RC) (PicoLab 5053 Rodent Diet 
20; Lab Diets) ad libitum.  In HFD feeding experiments, fasted glucose levels and 
glucose tolerance were assessed at 3 and 6 months after starting a HFD. To obtain age-
induced diabetic mice, we screened male and female mice at 15-26 months of age 
following the same criteria.  For IPGTTs, mice were fasted for 15 hrs, and 50% dextrose 
(2g/kg body weight) was injected intraperitoneally.  Blood was collected from the tail 
vein at 0, 15, 30, 60, and 120 min.  Blood glucose levels were measured by the Accu-
Chek II glucometer (Roche Diagnosis), and plasma insulin levels were determined using 
the Singulex Erenna immunoassay system at the Washington University Core Laboratory 
for Clinical Studies.  For insulin tolerance tests, mice were fasted for 4 hrs before they 
were injected with human insulin (0.75 U kg-1 body weight; Lilly).  Blood glucose levels 
were measured at 0, 15, 30, 45, and 60 min after insulin injection.  For lipid levels, 
cholesterol and triglycerides were measured using reagents from Thermo Electron 
Corporation (Waltham, MA), while non-esterified free fatty acid levels were measured 
using reagents from Wako (Richmond, VA) in the Washington University Animal Model 
Research Core associated with the Nutrition Obesity Research Center (NORC) and the 
Diabetes Research and Training Center (DRTC). 
 
Western blotting 
40-100 µg of whole tissue extracts were analyzed by Western blotting.  Anti-
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PBEF/NAMPT (Bethyl Laboratories), anti-NAMPT (Revollo et al., 2004), anti-tubulin 
(Santa Cruz), anti-actin (Calbiochem), anti-phospho-AKT (Ser473), and anti-AKT (Cell 
Signaling Technology) antibodies were used as primary antibodies.  Horseradish 
peroxidase-conjugated anti-rabbit IgG (Amersham and Cell Signaling Technology) and 
anti-mouse IgG (Amersham) antibodies were used as secondary antibodies.  Signals were 
visualized using the ECL detection system (Amersham). 
 
NAD+ and NMN measurements by HPLC 
Frozen tissues or cultured cells were extracted in perchloric acid and neutralized in 
K2CO3 on ice as described previously (Ramsey et al., 2009).  For NAD+ measurement, 
the HPLC was run at a flow rate of 1 ml/min with 100% buffer A from 0-5 min, a linear 
gradient to 95% buffer A/5% buffer B (100% methanol) from 5-6 min, 95% buffer A/5% 
buffer B from 6-11 min, a linear gradient to 85% buffer A/15% buffer B from 11-13 min, 
85% buffer A/15% buffer B from 13-23 min, and a linear gradient to 100% buffer A from 
23-24 min.  For NMN measurement, the HPLC was run at a flow rate of 1 ml/min with 
100% buffer A from 0-5 min, a linear gradient to 60% buffer A/40% buffer B from 5-10 
min, 60% buffer A/40% buffer B from 10-32.5 min, a linear gradient to 100% buffer A 
from 32.5-35 min.  NAD+ and NMN were usually eluted at 11 min and 20 min, 
respectively.  NAD+ and NMN levels were quantitated based on the peak area compared 
to a standard curve and normalized to weights of frozen tissues, protein content of 
primary hepatocytes, or to the number of primary islets. The NAD+ measurements in 
primary islets were conducted in triplicates of islets pooled from two or three individual 
mice and repeated twice.  NAD+ and NMN fractions from HPLC were further analyzed 
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and confirmed by LC/MS/MS. 
 
Mass spectrometry analysis of nicotinamide riboside (NR) 
Liquid chromatography-tandem mass spectrometry (LC/MS/MS) was performed with a 
Shimadzu 10A HPLC system (Shimadzu Scientific Instruments, Columbia, MD) coupled 
to a TSQ Quantum Ultra triple quadrupole mass spectrometer (Thermo Finnigan, San 
Jose, USA) in the positive mode.  NR was separated with the above HPLC system with a 
Hypercarb column.  The mobile phase was composed of 0.1% trifluoroacetic acid (TFA) 
in water (buffer A) and 0.1% TFA in 100% acetonitrile (buffer B).  The LC was run at a 
flow rate of 0.6 ml/min with 95% buffer A/5% buffer B from 0-0.2 min, a linear gradient 
to 50% buffer A/50% buffer B from 0.2-5 min.  The column was kept at 50% buffer 
A/50% buffer B until 6.0 min, reverted to 95% buffer A/5% buffer B by 6.1 min, and re-
equilibrated until 11.0 min.  NR in liver extracts was detected using the selected reaction 
monitoring (SRM) mode.  Two transitions were used; m/z 255 → 123 (quantification) 
and m/z 255 → 106 (confirmation).  Relative NR levels were quantitated based on the 
peak area and normalized to that at 0 min time point. 
 
Islet isolation and in vitro insulin secretion analysis 
Islets were isolated from HFD-fed mice as described previously (Revollo et al., 2007).  
For treatments with NMN, islets were cultured for 24 hrs in RPMI media containing 100 
µM NMN.  
 
Micoroarrays and bioinformatic analyses 
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For individual genes, raw microarray data were subjected to Z score transformation, and 
Z ratios were calculated as described previously (Cheadle et al., 2003).  False discovery 
rates for the differences in expression levels between two conditions (RC-fed vs HFD-fed 
or HFD-fed vs NMN-treated HFD-fed livers) were calculated using the Rank Product 
Analysis (Hong et al., 2006).  We identified genes whose expression levels were 
significantly altered between two conditions with the false discovery rate (FDR) less than 
5%.  The genes filtered by the Rank Product Analysis were ordered based on the sum of 
the absolute numbers of Z ratios, a parameter that reflects the extent of the alterations 
between HFD feeding and NMN treatment.  For the Parametric Analysis of Gene Set 
Enrichment (PAGE) analysis, GO biological process and GO molecular function gene 
sets (GO gene sets; http://www.broad.mit.edu/gsea/msigdb/msigdb_index.html) were 
used with our microarray data, and Z scores were calculated for each gene set, as 
previously described (Kim and Volsky, 2005).  All data were analyzed by the R statistical 
software package (available at www.bioconductor.org).  For the biological network 
analysis, the shortest path algorithm was used to deduce possible networks based on our 
microarray results using the MetaCore program (version 6.3) (GeneGo).  We also applied 
the transcription regulation (TR) algorithm to identify transcription factors that likely 
cause gene expression changes detected by our microarray analyses.  The total numbers 
of nodes were determined, and the probabilities of those links represented by zScore and 
gScore and their p-values were calculated based on hypergeometric distribution.  The 
resultant transcription factors were ranked by p-values. 
 
Indirect calorimetry measurements 
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Metabolic parameters were measured using an Oxymax indirect calorimetry system 
(Columbus Instruments, Columbus, OH) (Bernal-Mizrachi et al., 2002).  Two mice were 
housed per chamber with a 12-h light/ 12-h dark cycle in an ambient temperature of 23-
25°C.  VO2 and VCO2 were determined under Oxymax system settings as follows: air 
flow, 1.6 l/min; sample flow, 0.5 l/min; reference settling time, 2 min; and measuring 
time, 0.5 min.  The system was calibrated against a standard gas mixture to measure O2 
consumed (VO2, ml/g 0.75/h) and CO2 generated (VCO2, ml/g 0.75/h).  Oxygen consumption 
(VO2) and respiratory quotient (RQ; VCO2/ VO2) were evaluated over a 12-h period.  
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eNAMPT secretion from adipose tissue  









Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the 
NAD biosynthesis pathway in mammals. Interestingly, NAMPT has intra- and 
extracellular forms (iNAMPT and eNAMPT, respectively), and eNAMPT is secreted 
from adipose tissue as one of the adipokines.  However, the mechanism underlying the 
regulation of eNAMPT secretion has not been fully understood yet.  Here, we have 
demonstrated that deacetylation on NAMPT by SIRT1 controls its secretion from 
adipocytes.  iNAMPT is acetylated in both brown and white adipose tissues, and the level 
of acetylation of iNAMPT is decreased during fasting when Sirtuins are activated.  We 
also found that enhancement of eNAMPT secretion under low glucose culture condition 
in differentiated brown and white adipocytes is completely inhibited by nicotinamide 
(NAM), an inhibitor of SIRTs, suggesting that deacetylation by SIRTs is required to 
induce eNAMPT secretion by low glucose stimulus.  Consistently, eNAMPT levels in the 
blood were enhanced after 48 hours fasting in WT but not in Sirt1 KO mice, and 
iNAMPT acetylation levels are decreased while eNAMPT secretion is increased in 
differentiated adipocytes by SIRT1 overexpression.  In addition, iNAMPT physically 
interacts with SIRT1 in differentiated adipocytes, and this interaction is enhanced under a 
low-glucose culture condition, suggesting that SIRT1 deacetylates iNAMPT by direct 
interaction and increases eNAMPT secretion.  We have found five acetylation sites on 
iNAMPT and only 4 out of 5 were deacetylated.  SIRT1 is responsible for deacetylating 
lysine 53, which results in both increased enzymatic activity and secretion of eNAMPT.  
These results strongly support the notion that eNAMPT secretion is controlled by SIRT1-
mediated deacetylation.  Taken together, our results indicate a novel feedback loop 
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regulating systemic NAD biosynthesis through SIRT1 and eNAMPT and provide 
important insight into therapeutic and preventive intervention for metabolic diseases such 




Over the past decade, an accumulating body of evidence suggests that the biosynthesis of 
nicotinamide adenine dinucleotide (NAD), an essential coenzyme and important currency 
for cellular energy metabolism, plays a critical role in the regulation of diverse biological 
processes through key NAD-consuming mediators, including poly-ADP-ribose 
polymerases (PARPs), CD38/157 ectoenzymes, and sirtuins 1.  In mammals, NAD can be 
synthesized from four different substrates: two different forms of vitamin B3, namely, 
nicotinamide and nicotinic acid, tryptophan, and nicotinamide riboside (NR) 2.  Among 
them, nicotinamide is predominantly used to synthesize NAD in mammals 3.  The NAD 
biosynthesis starting from nicotinamide is catalyzed by two key enzymes: nicotinamide 
phosphoribosyltransferase (NAMPT) and nicotinamide mononucleotide 
adenylyltransferase (NMNAT) 4.  NAMPT, the rate-limiting enzyme in this NAD 
biosynthetic pathway, catalyzes the conversion of nicotinamide and 5-phosphoribosyl-
pyrophosphate to nicotinamide mononucleotide (NMN), a key NAD intermediate.  NMN, 
in turn, is adenylated by NMNAT to NAD 4. 
 NAMPT is a unique enzyme that has an ancient origin and an interesting 
research history.  NAMPT was originally identified as the product of the gene that 
confers the capability of synthesizing NAD from nicotinamide, called NadV, in the 
bacteria Haemophilus ducreyi 5.  Surprisingly, a set of genes encoding NAMPT and 
NMNAT homologues has been found even in some bacteriophages 6.  The biochemical 
and structural features of NAMPT have been extensively studied by our and other groups, 
clearly demonstrating that this protein belongs to a dimeric class of type II 
phosphoribosyltransferases 7,8.  Interestingly, NAMPT has two different forms in 
  78 
mammals: intra- and extracellular NAMPT (iNAMPT and eNAMPT, respectively).  
eNAMPT was previously identified as pre-B cell colony-enhancing factor (PBEF), a 
presumptive cytokine that enhances the maturation of B cell precursors in the presence of 
interleukin-7 (IL-7) and stem cell factor (SCF) 9, and visfatin, a visceral fat-derived 
adipokine that was once proposed to exert an insulin-mimetic function by binding to the 
insulin receptor 10.  Neither function of PBEF and visfatin has been confirmed to date.  
Indeed, we have clearly demonstrated that NAMPT functions as an intra- and 
extracellular NAD biosynthetic enzyme and that eNAMPT does not exert insulin-mimetic 
effects both in vitro and in vivo 4,11.  However, the physiological relevance and function 
of eNAMPT has still been controversial.  For instance, a number of studies implicate that 
eNAMPT might function as a proinflammatory cytokine, although the enzymatic activity 
still appears to be required in some cases 12-15.  Additionally, because NAMPT does not 
have a cleavable signal sequence 9, whether eNAMPT is positively secreted or passively 
produced due to cell lysis or cell death has been a significant debate. 
 Here we show that the secretion and the enzymatic activity of eNAMPT are 
regulated by SIRT1, the mammalian sirtuin family NAD-dependent deacetylase, in 
adipose tissues in response to glucose availability.  Deacetylation of iNAMPT at lysine 
53, a residue located close to the catalytic sites at the cleft of the NAMPT dimer, 
predisposes the protein to secretion and enhances its enzymatic activity in adipose 
tissues.  These findings open a new possibility that adipose tissue functions as a critical 
modulator for systemic NAD biosynthesis through the NAD/SIRT1-dependent regulation 
of the secretion and the enzymatic activity of eNAMPT. 
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RESULTS 
Acetylation levels of iNAMPT affect the secretion of eNAMPT 
We have previously demonstrated that fully differentiated brown and white adipocytes 
positively secrete eNAMPT, which is enzymatically twice as active as iNAMPT 11.  We 
speculated that a post-translational modification was likely responsible for the altered 
enzymatic activity and the secretion of eNAMPT.  During our intensive search for 
modifications on the NAMPT protein, we found that iNAMPT was acetylated in brown 
and white adipose tissue (BAT and WAT, respectively) (Figure 1A).  Interestingly, 
acetylation levels of iNAMPT decreased by ~50% in response to 48-hr fasting (Figure 
1A).  To recapitulate the alteration in iNAMPT acetylation in a cell culture system, we 
used differentiated HIB-1B brown adipocytes, which express a very high level of 
iNAMPT and secrete eNAMPT into culture supernatants.  In cell extracts from HIB-1B 
adipocytes, relatively low levels of acetylated iNAMPT were detected (Figure 1B, lane 
M).  Acetylation levels significantly increased when treating cells with trichostatin A 
(TSA) and nicotinamide, inhibitors of class I and II deacetylases and class III NAD-
dependent deacetylases, respectively (Figure 1B, right two T+N lanes).  In this condition, 
iNAMPT protein levels did not change in cell extracts, whereas secreted eNAMPT 
protein levels in culture supernatants decreased by ~60% (Figure 1C), implicating that 
the acetylation status of iNAMPT might predispose the protein to secretion.  Because 
fasting decreased acetylation levels of iNAMPT in adipose tissue, we examined the 
effects of low glucose in media on iNAMPT acetylation and eNAMPT secretion in HIB-
1B cells.  The detection of decreased iNAMPT acetylation turned out to be technically 
difficult due to relatively low levels of acetylated iNAMPT in HIB-1B cells.  
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Nonetheless, lowering glucose dramatically enhanced eNAMPT secretion 3.5 to 5.5-fold 
in differentiated HIB-1B cells and 3T3-L1 white adipocytes (Figure 1D).  Furthermore, 
nicotinamide completely inhibited the enhancement of eNAMPT secretion by low 
glucose (Figure 1D), suggesting that deacetylation of iNAMPT by nicotinamide-sensitive 
sirtuin family members might be responsible for the low glucose-induced enhancement of 
eNAMPT secretion. 
 
SIRT1 regulates eNAMPT secretion by physically interacting with and deacetylating 
iNAMPT 
It has been well known that the enzymatic activity of Sirtuins is effectively inhibited by 
nicotinamide in culture 16.  Among them SIRT1 is the direct homologue of the yeast Sir2, 
the first member of the Sirtuin family, having a broad range of targets 17,18.  Therefore, we 
hypothesized that SIRT1 might regulate eNAMPT secretion in adipose tissue.  To address 
this possibility, we examined whole-body Sirt1 knockout (Sirt1-/-) mice in the FVB 
background.  Different from other Sirt1-/- mouse lines in the B6 or 129 backgrounds, 
these FVB Sirt1-/- mice do not die postnatally and can grow into adulthood 19.  In Sirt1+/+ 
mice, plasma eNAMPT levels showed moderate, but significant increases in response to 
48-hr fasting (Figure 2A).  However, these increases were completely abrogated in Sirt1-/- 
mice (Figure 2A).  Intriguingly, iNAMPT significantly accumulated in the WAT of Sirt1-/- 
mice compared to Sirt1+/+ mice, whereas the iNAMPT protein levels did not differ in the 
liver between Sirt1+/+ and Sirt1-/- mice (Figure 2B).  Given that Nampt mRNA levels 
were indistinguishable in WAT between Sirt1+/+ and Sirt1-/- mice (Figure 2C), this 
abnormal accumulation of iNAMPT in Sirt1-/- WAT is likely associated with the defect in 
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eNAMPT secretion in Sirt1-/- mice. 
 To further examine the connection between SIRT1 and eNAMPT secretion, we 
infected differentiated HIB-1B adipocytes with adenoviruses carrying either Sirt1 or Gfp 
expression vectors and measured eNAMPT secretion.  Overexpression of SIRT1 
enhanced eNAMPT secretion 2.3-fold compared to GFP controls in differentiated HIB-
1B cells (Figure 3A).  We further confirmed this result by introducing both NAMPT and 
SIRT1 into HEK293 cells.  Again, overexpression of SIRT1 enhanced eNAMPT 
secretion, and the effect was much more dramatic in HEK293 cells (~11-fold) compared 
to that in differentiated HIB-1B cells (Figure 3B).  In this condition, we assessed the 
acetylation status of iNAMPT.  Acetylated iNAMPT was detected only in the presence of 
TSA and nicotinamide, and iNAMPT acetylation levels significantly decreased by SIRT1 
overexpression (Figure 3C).  These results, in combination with the results from Sirt1-/- 
mice, suggest that SIRT1-mediated deacetylation of iNAMPT predisposes the protein to 
be secreted from differentiated adipocytes. 
 Because SIRT1 tends to physically interact with its deacetylation targets, we 
also examined whether SIRT1 and iNAMPT physically interact in differentiated 
adipocytes.  Indeed, SIRT1 and iNAMPT did interact in differentiated HIB-1B adipocytes 
(Figure 3D).  Interestingly, the interaction between SIRT1 and iNAMPT appeared to be 
enhanced by low glucose (Figure 3D, right two lanes).  Although SIRT1 is usually 
considered as a nuclear sirtuin, we found that a considerable amount of SIRT1 was 
localized in the cytoplasmic fractions from differentiated HIB-1B and 3T3-L1 cells 
(Figures 3E and S1).  iNAMPT was primarily localized in the cytoplasm of these 
adipocytes (Figures 3E and S3).  Therefore, these results suggest that SIRT1 physically 
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interacts with and deacetylates iNAMPT in the cytoplasm of differentiated adipocytes, 
promoting the secretion of eNAMPT. 
 
Deacetylation of lysine 53 on iNAMPT enhances eNAMPT secretion 
We next attempted to determine which acetylated residues of iNAMPT are important for 
the regulation of eNAMPT secretion.  We established HEK293 and differentiated HIB-1B 
cells expressing C-terminally FLAG-tagged iNAMPT, and FLAG-tagged iNAMPT and 
eNAMPT proteins were purified from those cell extracts and culture supernatants, 
respectively.  These purified NAMPT proteins, as well as the bacterially produced 
recombinant NAMPT protein, were subjected to a mass spectrometric analysis of protein 
modification.  Five lysines, K53, K79, K107, K331, and K369, were found to be 
acetylated on iNAMPT, whereas only K369 was acetylated on eNAMPT (Figures 4A and 
S2).  Surprisingly, four out of the five lysines were also acetylated on bacterially 
produced recombinant NAMPT, although it did not have acetylated K107 but acetylated 
K339 (Figure 4A), implying that the regulation of NAMPT acetylation might be 
conserved from bacteria to mammals.  Among these acetylated lysines, the location of 
K53 on the crystal structure of iNAMPT is particularly interesting.  NAMPT is a dimeric 
type II phosphoribosyltransferase, and K53, which protrudes from each monomer, is 
nicely aligned along the “cleft” of the dimer and located very close to the catalytic sites 
(Figure 4B).  Contrarily, K79 is located along the other cleft on the opposite side of the 
dimer to the one containing K53 (Figure 4B).  The other acetylated lysines are located on 
surrounding α-helices on both sides of the dimer.  Therefore, we decided to introduce the 
deacetylation-mimicking K-to-R mutation into K53 and/or K79 and examined the 
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acetylation levels of each mutant iNAMPT, in the presence or absence of SIRT1, 
compared to that of the wild-type NAMPT protein in HEK293 cells.  Whereas the wild-
type and K79R mutant iNAMPT proteins showed SIRT1-dependent deacetylation, the 
K53R and K53/79R mutant iNAMPT proteins displayed reduced acetylation levels and 
did not show further reduction in acetylation levels by SIRT1 (Figure 4C), suggesting that 
K53 is the SIRT1-dependent acetylation site on iNAMPT.  We then examined the 
enzymatic activity and the secretion of this K53R mutant, as well as another mutant 
K53A and the wild-type NAMPT protein in differentiated HIB-1B adipocytes that 
express FLAG-tagged versions of these proteins.  The enzymatic activity of both K53R 
and K53A mutants did not differ from that of the wild-type protein (Figure 4D).  
However, the secretion of these mutant proteins was 2.5 to 3-fold higher than that of the 
wild-type protein (Figure 4E), strongly suggesting the importance of this particular lysine 
and its deacetylation for the regulation of eNAMPT secretion.  Conversely, the 
introduction of the acetylation-mimicking K-to-Q mutation into K53 significantly 
decreases the enzymatic activity and the secretion of the protein (Figures 4F and 4G), 
suggesting that acetylation of lysine 53 suppresses NAMPT enzymatic activity and also 
prevents the protein from being secreted.  Taken together, these results demonstrate that 







In our previous study, we have shown that eNAMPT is positively secreted by fully 
differentiated adipocytes through an unidentified non-classical secretory pathway.  We 
have also shown that eNAMPT possesses significantly higher enzymatic activity 
compared to iNAMPT, implying that the secretion and the enzymatic activity of 
eNAMPT might be regulated in a coordinated manner.  Our present study clearly 
demonstrates that the secretion and the enzymatic activity of eNAMPT are regulated by 
SIRT1-dependent deacetylation in adipocytes.  First, iNAMPT is acetylated in WAT and 
BAT, and its acetylation levels decrease in response to fasting.  Second, in differentiated 
adipocyte cultures, lowering glucose increases eNAMPT secretion, and nicotinamide, an 
inhibitor of SIRT1 enzymatic activity, completely abrogates the low glucose-induced 
increase in eNAMPT secretion.  Third, Sirt1-/- mice fail to show fasting-induced increases 
in plasma eNAMPT levels and show abnormal accumulation of iNAMPT in WAT.  
Fourth, in differentiated adipocytes, SIRT1 decreases iNAMPT acetylation levels and 
increases eNAMPT secretion through its physical interaction with NAMPT, whereas 
treatment with nicotinamide and trichostatin A increases iNAMPT acetylation and 
decreases eNAMPT secretion.  Lastly, lysine 53, which is located close to the catalytic 
sites of dimeric NAMPT, is the SIRT1-sensitive acetylation site.  Deacetylation-mimetic 
K-to-R mutation of this particular lysine increases eNAMPT secretion, whereas 
acetylation-mimetic K-to-Q mutation decreases the secretion and the enzymatic activity 
of eNAMPT in differentiated adipocytes.  Whether eNAMPT is positively secreted or is 
produced simply due to cell lysis or cell death has been a serious debate.  However, in 
this present study, our results provide compelling evidence that eNAMPT secretion is a 
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highly regulated process in adipose tissue in response to changes in nutritional 
availability. 
Our and other groups have previously demonstrated that SIRT1 and NAMPT 
comprise a novel transcriptional-enzymatic feedback loop that produces a circadian 
oscillation of NAD in peripheral tissues 20,21.  Our present study has revealed that SIRT1 
and NAMPT comprise another NAD-regulatory feedback loop through the regulation of 
eNAMPT secretion in adipose tissue.  In this new mechanism, SIRT1-dependent 
deacetylation of iNAMPT at lysine 53 predisposes the protein to secretion.  The 
deacetylation event seems to occur in the cytoplasm of differentiated adipocytes, and 
approximately 0.5% of iNAMPT per hour is estimated to be secreted as eNAMPT in 
differentiated HIB-1B adipocytes (data not shown), suggesting that a very specific 
fraction of iNAMPT is destined to enter this SIRT1-dependent secretory machinery. 
Experiments with K-to-R and K-to-Q mutants of lysine 53 demonstrate that the 
acetylation status of lysine 53 is critical to determine the fate of iNAMPT.  Because the 
K53A mutation also significantly increases eNAMPT secretion, lysine 53 per se appears 
to play an important role in determining the fate of iNAMPT, possibly providing a 
docking site to an unidentified factor that might interact with acetylated lysine 53 of 
iNAMPT and prevent it from secretion (Figure 5).  Interestingly, it has been reported that 
in monocytes and macrophages activated by inflammatory stimuli, High Mobility Group 
protein 1 (HMGB1), a highly conserved chromatin architectural protein, is 
hyperacetylated and secreted as a proinflammatory cytokine 22.  In the case of HMGB1, 
hyperacetylation triggered by inflammatory stimuli redirects the protein from the nucleus 
to the cytoplasm and then to secretory lysosomes.  Given that NAMPT has also been 
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reported to be nuclear, acetylation on specific lysines might be important to keep 
iNAMPT in the cytoplasmic compartment, sequestering it from secretion and nuclear 
transport. 
 Acetylation is also important to regulate the enzymatic activity of NAMPT.  We 
identified five acetylation sites on iNAMPT, and four out of these five sites are 
deacetylated on eNAMPT.  Interestingly, the enzymatic activity of iNAMPT is 2-fold 
lower than that of eNAMPT, and the K53Q mutant can recapitulate this acetylation-
dependent reduction in the enzymatic activity.  Lysine 53 is distinguished from other 
lysine residues because it is located at the “cleft” that contains the catalytic sites, 
although the other lysines might have other functions in different biological contexts.  
These results suggest that acetylation/deacetylation might induce a conformational 
change in the NAMPT structure and regulate its enzymatic activity.  It will be of great 
interest to examine what effects the acetylation of lysine 53 makes on the structure of the 
catalytic sites and dimer formation of NAMPT.  Because NAD drives SIRT1 activity in a 
circadian oscillatory manner, it is also likely that the deacetylation and the secretion of 
eNAMPT follow circadian oscillation.  Indeed, plasma eNAMPT levels appear to show 
diurnal oscillation in mice, although it is still unclear whether this oscillation is produced 
by an intrinsic clock mechanism (Yoon and Imai, unpublished observation).  Although 
where exactly NMN is synthesized by eNAMPT still remains unsolved, our findings 
provide an interesting possibility that the intimate interplay between SIRT1 and NAMPT 
contributes to multi-layered feedback loops regulating the dynamics of NAD biosynthesis 
within and between tissues and organs. 
In conclusion, our finding that adipose tissue actively regulates the secretion 
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and the enzymatic activity of eNAMPT in an NAD/SIRT1-dependent manner provides 
strong support to the idea that adipose tissue functions as a critical determinant for the 
spatial and temporal coordination of NAD biosynthesis throughout the body.  This 
systemic coordination of NAD biosynthesis might play an important role in orchestrating 
metabolic responses in multiple tissues and maintaining metabolic homeostasis against 
nutritional and environmental perturbations.  In this highly coordinated systemic network, 
adipose tissue modulates the functions of remote tissues through the NAD/SIRT1-
dependent regulation of eNAMPT secretion.  This model also predicts that having an 
optimal amount of adipose tissue might be beneficial to maximize the robustness of the 
physiological system through the regulation of a proper amount of eNAMPT secretion.   
Further investigation of the dynamics of NAD on a systemic level will provide further 
insight into the role of adipose tissue as a critical modulator for the regulation of systemic 




Detection of intracellular NAMPT and SIRT1 in tissues, and of extracellular 
NAMPT in plasma 
Mice fed ad libitum or fasted for 48 hours were euthanized by carbon dioxide 
asphyxiation.  Organs were immediately collected, homogenized in 1X Laemmli’s 
sample buffer using a Polytron (Kinematica, Switzerland), and boiled for 5 minutes.  
Samples were then centrifuged at 16000g and protein concentrations were measured by 
the Bradford assay (Bio-Rad, CA). Before euthanization, plasma from mice fed ad 
libitum or fasted for 48 hours was collected by centrifuging blood at 3200g for 5 minutes 
at 4°C and immediately boiled for 5 minutes in 1X Laemmli’s sample buffer.  Tissue 
extracts and plasma samples were analyzed by Western blotting with anti-NAMPT 
(Bethyl Laboratories, TX) or anti-SIRT1 (Sigma, MO) antibodies. 
 
Detection of acetylated NAMPT in adipose tissue and differentiated HIB-1B cells 
WAT or BAT collected from mice was homogenized in 1X RIPA buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1% Igepal CA630, 0.5% Sodium deoxycholate, 0.1% SDS, 
1 mM EDTA, 1 mM NaF, 10 µM trichostatin A, 10 mM nicotinamide, 0.5 mM DTT, 
protease inhibitor cocktail (Roche, Germany)). Cell extracts were immunoprecipitated 
with anti-acetyl lysine conjugated beads (ImmuneChem, Canada) overnight. 
Immunoprecipitates were eluted with 1X Laemmli’s sample buffer, boiled for 5 minutes, 
and analyzed by Western blotting with anti-Nampt antibody (OMNI379, Enzo Life 
Science, NY).  Fully differentiated HIB-1B cells were homogenized in NAMPT-IP buffer 
(PBS [pH 7.4], 0.5% NP-40, 1 mM EDTA, 1 mM NaF, 10 µM TSA, 10 mM 
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nicotinamide, 0.5 mM DTT, protease inhibitor cocktail (Roche, Germany)) in a similar 
way, except that anti-acetyl lysine antibody (Cell signaling, MA) and protein A agarose 
(Sigma, MO) were used for immunoprecipitation.      
 
RNA isolation and analysis 
Total RNA from WAT and BAT was isolated using the RNeasy lipid tissue mini-kit 
(Qiagen, CA). Total RNA from all other tissues was isolated using the RNeasy mini-kit 
(Qiagen, CA). cDNA was synthesized using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA) with random primers. Quantitative real-time 
PCR was performed using the 7500 Fast Real-Time PCR system (Applied Biosystems, 
CA).  Relative expression levels were determined based on the CT values and normalized 
to Gapdh. 
 
Differentiation of 3T3L1 and HIB-1B preadipocyte cell lines 
All cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal bovine serum and antibiotics. Confluent cultures of HIB-1B brown pre-
adipocytes were differentiated by adding 0.5 mM isobutylmethylxanthine (IBMX), 1 mM 
dexamethasone, 5 mg/ml insulin, and 1 nM triiodothyronine (T3) for 2 days and then 
changing to the media containing 5 mg/ml insulin and 1 nM T3 every other day for 6 
more days. 3T3-L1 white pre-adipocytes were differentiated similarly, except that T3 was 
absent in the media through the whole differentiation process. All chemicals were 
purchased from Sigma.  
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Generation of HIB-1B cells stably expressing wild type or mutant Nampt-FLAG 
A C-terminally FLAG-tagged Nampt (Nampt-FLAG) was created and cloned into the 
mammalian expression vector pCXN2 as described previously 11(Revollo et al., Cell 
Metabolism, 6:363). Each lysine mutant Nampt-FLAG was generated using the 
QuikChange II Site-Directed Mutagenesis Kit (Stratagene, CA) according to the 
manufacturer’s protocol. To create HIB-1B cells expressing Nampt-FLAG or mutant 
Nampt-FLAG, HIB-1B cells were transfected (Superfect, QIAGEN, CA) with pCXN2-
Nampt-FLAG or pCXN2-mutant Nampt-FLAG. Transfected HIB-1B cells were selected 
by incubating with 500 µg/ml of G418 (Invitrogen, CA) for 2 weeks. Before the secretion 
assay and the enzymatic reactions, HIB-1B cells were fully differentiated as described 
above.  
 
MS analysis of acetylated lysine sites on NAMPT 
Recombinant mouse NAMPT was expressed and prepared as described previously 4. 
iNAMPT and eNAMPT was immunoprecipitated from HEK293 cells and from media of 
differentiated HIB-1B cells expressing Nampt-FLAG, respectively, as described above. 
Each protein was resolved by 10% SDS/PAGE and visualized by Coomassie blue 
staining. The bands of protein were excised and subjected to MS analysis provided by the 
Taplin Biological Mass Spectrometry Facility at Harvard Medical School.  
 
eNAMPT secretion assay 
3T3L1 or HIB-1B cells were differentiated as described above. To detect endogenous 
iNAMPT or eNAMPT, cell extracts or culture supernatant were collected, respectively, 
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immunoprecipitated as described previously 11, and analyzed by Western blotting with 
anti-NAMPT antibody (Bethyl Laboratories, TX).  HEK293 cells transfected with 
Nampt-FLAG and HIB-1B cells stably expressing Nampt-FLAG were processed in the 
same way, except that anti-FLAG beads (M2, Sigma, MO) were used for 
immunoprecipitation.  eNAMPT secretion levels were calculated by measuring and 
quantifying the amount of iNAMPT and eNAMPT by Western blotting. 
 
Enzymatic reactions 
Nampt enzymatic reactions were conducted as previously described 11. For 
immunoprecipitation of intracellular Nampt-FLAG, whole cell extracts were prepared 
with NAMPT-IP buffer and mixed with anti-FLAG-M2 conjugated beads (Sigma, MO) 
for 2-3 hours at 4°C. For immunoprecipitation of extracellular Nampt-FLAG, HIB-1B 
culture supernatants were collected after incubating differentiated HIB-1B cells overnight 
with DMEM without fetal bovine serum but supplemented with 5 mg/ml insulin and 1 
nM triiodothyronine, centrifuged at 3000 rpm for 2 min at 4°C, concentrated 8 to 10 fold 
with Amicon Ultra-15 columns (Milipore, MA), and mixed with anti-FLAG beads for 2-3 
hours at 4°C. Immunoprecipitates were washed twice with IP-buffer and twice with PBS. 
Immunoprecipitates on anti-FLAG beads were incubated in enzymatic reaction 
buffer (50 mM Tris-HCl, pH 8.5, 100 mM NaCl, 0.25 mM nicotinamide, 10 mM MgSO4, 
1.5% ethanol, 0.5 mM phosphoribosyl phyrophosphate (PRPP), 2 mM ATP) for 55 min at 
37°C. After this reaction, mouse recombinant NMNAT and yeast alcohol dehydrogenase 
were added at a final concentration of 10 mg/ml each, and the mixture was incubated for 
5 min at 37°C. Supernatants were collected by spinning down anti-FLAG beads, and 
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auto-fluorescence of NADH was measured in a PerkinElmer LS 50B fluorometer (340 
nm excitation, 460 nm emission). NADH auto-fluorescence values were converted to the 
amount of NMN using a standard curve drawn with known amounts of NMN. 
Immunoprecipitates bound on anti-FLAG beads were extracted with 1X Laemmli’s 
buffer, boiled for 5 min, and analyzed by Western blotting with anti-Nampt antibody. The 
amounts of Nampt used for enzymatic reactions were quantitated compared to the 
standards of mouse recombinant NAMPT. Kcat values were calculated based on the 
molar amount of NMN generated per molar amount of immunoprecipitated Nampt-
FLAG proteins per unit time.    
 
Subcellular protein fractionation 
Cytoplasmic and nuclear protein fractions were separated and prepared using the 
Subcellular Protein Fractionation Kit (Thermo Scientific, IL) according to the 
manufacturer’s protocol.  
 
Statistical Analysis 
Differences between two groups were assessed using the Student’s t test.  Comparisons 
among several groups were performed using one-way ANOVA with the Fisher’s LSD 
post-hoc test.  p values less than 0.05 were considered statistically significant.  
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FIGURE LEGENDS 
Figure 1.  iNAMPT acetylation status in adipose tissue regulates eNAMPT secretion. 
(A)  iNAMPT acetylation levels in brown adipose tissue (BAT) and white adipose 
tissue (WAT) of FVB WT mice.  The right panel represents the average value of 
two independent experiments.  Each value is normalized to the fed values.   
(B)  iNAMPT acetylation levels in differentiated HIB-1B cells.  
(C)  Reduction of eNAMPT levels after TSA and Nicotinamide treatment in 
differentiated HIB-1B cells. eNAMPT secretion levels were calculated as 
(eNAMPT levels/iNAMPT levels)/the amount of total protein in cell lysates after 
quantifying Western blotting results.  
(B and C) Cells were treated with TSA and nicotinamide for 3 hours. T= TSA (5 
mM);    N= nicotinamide (5 mM); M= Mock (Ethanol) 
(D)  Changes in eNAMPT secretion levels in differentiated HIB-1B cells and 3T3L1 
cells. Cells were incubated with high glucose (H, 25 mM) or low glucose (L, 5 
mM) media in the presence or absence of nicotinamide (N, 5 mM) for 3 hours. 
eNAMPT secretion levels were calculated as eNAMPT levels /(iNAMPT 
levels/ACTIN)/the amount of total protein in cell lysates by quantifying Western 
blotting results. 
      (C and D) The bottom panels represent the average value of three independent 
experiments. Each value is normalized to the mock (C) or to the high glucose 
condition (D) values.  
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      Data were analyzed by the Student’s t test and one-way ANOVA with Fisher’s LSD      
post-hoc test. All values are presented as mean ± SEM.  *p < 0.05; **p < 0.01; ***p 
< 0.005. 
 
Figure 2.  eNAMPT secretion is increased during fasting in a SIRT1 dependent 
manner.  
(A)  Plasma eNAMPT levels from fed or fasted (48 hours) Sirt1+/+ and  
Sirt1-/- mice (n= 7-12).  The bottom panel represents eNAMPT levels of each 
condition normalized to the fed Sirt1+/+ level. 
(B)  iNAMPT and SIRT1 protein levels in the WAT and the liver of Sirt1+/+ and 
Sirt1-/- mice. iNAMPT levels were normalized to TUBULIN.  The right panel 
represents each condition normalized to the fed values. 
(C)  Quantitative RT-PCR results for Nampt mRNA expression in the WAT of Sirt1 
+/+ and Sirt1-/- mice (n= 4). 
Data were analyzed by the Student’s t test and one-way ANOVA with the Fisher’s 
LSD post-hoc test. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; 
***p < 0.005. 
 
Figure 3.  SIRT1 regulates eNAMPT secretion by deacetylating iNAMPT.  
(A and B) Increase of eNAMPT secretion by SIRT1 overexpression in differentiated 
HIB-1B cells (A) and in HEK293 cells (B), respectively. eNAMPT secretion 
levels were calculated as (eNAMPT levels/iNAMPT levels)/ the amount of total 
protein in cell lysates (A) or as (eNAMPT levels/ACTIN levels)/the amount of 
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total protein in cell lysates (B) by quantifying Western blotting results.  The right 
panels represent the average value of three independent experiments. Each value 
is normalized to the GFP (A) or to the NAMPT (B) values. 
(C) Decrease of iNAMPT acetylation by SIRT1 overexpression in HEK293 cells.  
Cells were incubated in the absence or presence of TSA (T, 5 mM) and 
nicotinamide (N, 5 mM) overnight prior to cell lysis.  Acetylation levels are 
normalized to iNAMPT levels.  The right panel represents iNAMPT acetylation 
levels of each condition normalized to the fed values.  
(D) Interaction between SIRT1 and iNAMPT in differentiated HIB-1B cells.  
(E) iNAMPT and SIRT1 expression after subcellular fractionation of                
differentiated HIB-1B cells.  Expression of GAPDH and TBP were used for the 
cytoplasmic and nuclear markers, respectively.   
(D and E) Cells were incubated with media containing high glucose (H, 25mM) or 
low glucose (L, 5 mM) overnight (D) or for 3 hours (E). 
Data were analyzed by the Student’s t test.  All values are presented as mean ± SEM. 
*p < 0.05; **p < 0.01; ***p < 0.005. 
 
Figure 4.  Lysine 53 acetylation status on iNAMPT is important in regulating 
eNAMPT secretion and enzymatic activity.  
(A)  NAMPT lysine acetylation sites. iNAMPT and eNAMPT were prepared from 
cell lysate of HEK293 and culture supernatant of differentiated HIB-1B cells, 
respectively, overexpressing Nampt-FLAG. HEK293 cells overexpressing 
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Nampt-FLAG were treated with TSA (5 mM) and nicotinamide (5 mM) overnight 
prior to cell lysis. Recombinant NAMPT was prepared from bacteria. 
(B)  NAMPT structure with K53 and K79 acetylation sites shown (arrows). 
Monomers are indicated by orange and green, NMN bound to the catalytic site is 
shown in blue. 
(C)  Changes in WT or mutant iNAMPT acetylation status by SIRT1 overexpression 
in HEK293 cells.  Cells were treated with TSA (5 mM) and nicotinamide (5 mM) 
overnight prior to cell lysis. 
(D and F) The relative enzymatic activity of WT and NAMPT mutants in 
differentiated HIB-1B cells.  The enzymatic activity was calculated as the amount 
of nicotinamide mononucleotide (NMN) synthesis measured using the enzyme-
coupled flourometric assay divided by the amount of immunoprecipitated 
NAMPT quantified by western blotting (data not shown).  Values of WT or each 
NAMPT mutant were normalized to the WT enzyme activity value.  
(E and G) Comparison of eNAMPT secretion between WT and mutant NAMPT. 
eNAMPT secretion levels were calculated as (eNAMPT levels/iNAMPT 
levels)/the amount of total protein in cells lysates. eNAMPT and iNAMPT levels 
were measured by quantifying Western blotting results. Each value was 
normalized to the WT value.  
Each panel represents the average value of three independent experiments. Data were 
analyzed by the Student’s t test and one-way ANOVA with the Fisher’s LSD post-hoc  
      test. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.005. 
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Figure S1. SIRT1 is expressed in both the cytoplasm and nucleus of differentiated 
3T3 L1 cells. 
Fully differentiated 3T3L1 cells were incubated with the media containing high glucose 
(H, 25mM) or low glucose (L, 5 mM) for 3 hours.  Expressions of GAPDH and TBP 








Figure S2. Acetylation on K53 and K79 of NAMPT are identified through MS/MS 
analysis. 
MS/MS analysis of the peptide including K53 (A) and K79 (B) from mouse NAMPT.  K* 
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indicates acetylated lysine.  Left panels are the display from the search algorithm. Labels 
b and y designate the N- and C-terminal fragments, respectively, of the peptide produced 
by breakage at the peptide bond in the mass spectrometer. The number represents the 
number of N- or C- terminal residues present in the peptide fragment. Right panels are 











eNAMPT secreted from adipose tissue  











Adipose tissue functions as an endocrine organ secreting a variety of humoral factors, 
called adipokines.  Through the secretion of adipokines, adipose tissue regulates glucose 
and lipid metabolism and controls energy homeostasis at a systemic level.  Nicotinamide 
phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD biosynthesis in 
mammals, has two different forms, intracellular and extracellular NAMPT (iNAMPT and 
eNAMPT, respectively), and eNAMPT is secreted from adipose tissue as one of the 
adipokines.  Previously, we demonstrated that eNAMPT secretion is actively regulated by 
SIRT1 in response to nutrient availability, however, the function underlying the secretion 
of eNAMPT from adipose tissues is not fully understood yet.  In an effort to address this 
question, we generated adipocyte-specific Nampt KO (ANKO) mice.  We first confirmed 
that female ANKO mice show significant reductions in plasma eNAMPT levels.  
Interestingly, female ANKO show reduction of NAD levels not only in white and brown 
adipose tissue but also in the hypothalamus compared to control Namptflox/flox mice, 
suggesting that loss of Nampt only in adipose tissues could also influence hypothalamic 
function, including governing glucose homeostasis by lowering NAD levels in this tissue.  
Consistent with this notion, female ANKO exhibit severely impaired glucose tolerance 
and glucose-stimulated insulin secretion accompanied by hyperinsulinemia. 
Administration of NMN partially restores insulin sensitivity, but almost completely 
ameliorates the responsiveness of pancreatic β cells to glucose and hyperinsulinemia in 
vivo.  Taken together, our results suggest the new possibility that adipose tissues play an 
important role in maintaining glucose homeostasis by controlling eNAMPT secretion and 
eNAMPT-mediated NAD biosynthesis at a systemic level.        
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INTRODUCTION 
The adipocytes are highly specialized cells playing critical roles in energy regulation and 
homeostasis in that one organelle, the lipid droplet, encompasses greater than 95% of the 
entire cell body 1.  Adipocytes store energy in the form of triglycerides when energy 
intake exceeds expenditure and release it in the form of free fatty acids during starvation.  
Hence, the adipose tissue has been long considered as a passive and inactive organ that is 
primarily involved in energy storage.  However, it is now clear that adipose tissue has 
additional roles in energy regulation via endocrine, paracrine, and autocrine signals.  It 
has an exceptionally active secretory pathway whose function is not only to release lipids 
but also to secrete many endocrine and paracrine factors such as leptin, resistin, and 
TNFα, commonly referred to as adipokines 1.  Through release and circulation of these 
adipokines, adipose tissue has a role in regulating metabolism systemically, signaling to 
peripheral tissues such as liver and muscle and to the central nervous system through the 
hypothalamus, as well as to neighboring adipocytes and other local cell types within 
adipose tissue such as macrophages 1-3.       
  Nicotinamide phosphoribosyltransferase (NAMPT), originally identified as the 
product of the gene that confers the capability of synthesizing NAD from nicotinamide in 
Haemophilus ducreyi 4, has two different forms in mammals: intra- and extracellular 
NAMPT (iNAMPT and eNAMPT, respectively).  iNAMPT protein is expressed in almost 
all tissues although its expression levels is tissue dependent, 5 and only a few tissues, 
including adipose tissue, are able to secrete eNAMPT 6,7.   While the function of 
iNAMPT has been firmly established as the rate-limiting enzyme to synthesize NAD 
from nicotinamide in mammals, physiological relevance and function of eNAMPT has 
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still been controversial.  For instance, eNAMPT had been suggested to have insulin-
mimetic properties by directly binding to the insulin receptor, but this function has not 
been confirmed yet 8.  In addition, a number of studies implicate that eNAMPT might 
function as a proinflammatory cytokine, although the enzymatic activity appears to be 
still required in some cases 9-12.  Since we demonstrated that eNAMPT also functions as 
an NAD biosynthetic enzyme using an in vitro culture system, we have been 
investigating the function of eNAMPT in vivo using genetically engineered mice.  In 
pancreatic β cell-specific Sirt1 overexpressing (BESTO) mice, Sirt1 significantly 
promotes glucose-stimulated insulin secretion and improves glucose tolerance in vivo 13.  
However, Sirt1 activity is significantly reduced in aged β cells, which leads aged BESTO 
mice to completely lose all phenotypes of enhanced β cell function 14.  This seems to be 
due to a reduction in plasma NMN levels over age, and consistent with this notion, 
administration of nicotinamide mononucleotide (NMN) restores enhanced glucose-
stimulated insulin secretion and improved glucose tolerance in aged BESTO mice.  Along 
the same lines, female Nampt+/- mice, which have reduced plasma eNAMPT compared to 
WT, exhibit impaired glucose tolerance due to a defect in glucose-stimulated insulin 
secretion 6.  Primary female Nampt+/- islets also show a defect in NAD biosynthesis and 
glucose-stimulated insulin secretion, and, remarkably, administration of NMN can 
completely ameliorate this glucose-stimulated insulin secretion defect in female Nampt+/- 
mice.  These data clearly suggest that NAMPT-mediated NAD biosynthesis is necessary 
to maintain normal glucose-stimulated insulin secretion in pancreatic β cells.  However, 
these results still do not answer the question whether plasma eNAMPT protein itself is 
required to maintain normal levels of NAD biosynthesis in pancreatic β cells over age in 
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order to prevent age-related decline in glucose-stimulated insulin secretion.        
In the previous chapter, I showed that the secretion and the enzymatic activity 
of eNAMPT are regulated by SIRT in adipose tissue in response to nutritional changes.  
These findings suggest the possibility that adipose tissue plays a critical role in the 
maintenance of metabolic homeostasis by regulating eNAMPT secretion and NAD 
biosynthesis at a systemic level.  Then what is the function of plasma eNAMPT 
specifically secreted and regulated by adipose tissue?  In an effort to address this 
question, we generated adipose tissue-specific Nampt knockout (ANKO) mice.  
Consistent with our previous findings, female ANKO mice show significant reductions in 
plasma eNAMPT levels and NAD levels not only in white and brown adipose tissue but 
also in the hypothalamus, resulting in severe impairments in insulin sensitivity and 
glucose-stimulated insulin secretion.  Interestingly, treatment with NMN completely 
restores the normal responsiveness of pancreatic β cells to glucose in vivo, while the 
restoration of insulin sensitivity is partial, suggesting that pancreatic β cell function is 
supported by adipose tissue, likely through the extracellular NMN supply mediated by 
eNAMPT.  These findings open a new possibility that adipose tissue functions as a 
critical modulator for systemic NAD biosynthesis through the NAD/SIRT1-dependent 




ANKO mice exhibit reduced plasma eNAMPT levels and defects in NAD 
biosynthesis not only in adipose tissue but also in remote tissues 
Given that the secretion and enzymatic activity of eNAMPT are highly regulated by 
SIRT1-dependent deacetylation in differentiated adipocytes (Chapter 3), eNAMPT 
secreted by adipose tissue likely has physiological relevance as an extracellular NAD 
biosynthetic enzyme.  To address this hypothesis, we generated adipose tissue-specific 
Nampt knockout (ANKO) mice by crossing floxed Nampt (Namptflox/flox) mice and 
adiponectin-Cre driver mice (See Experimental Procedures).  ANKO mice were born 
following the Mendelian ratio and looked overtly normal.  As expected, ANKO mice 
showed a complete lack of iNAMPT expression in visceral WAT and BAT, although trace 
amounts of iNAMPT remained in subcutaneous WAT (Figure 1A).  Consistent with the 
lack of iNAMPT, NAD levels were dramatically reduced to 7-28% of the control 
Namptflox/flox mice in ANKO WAT and BAT (Figure 1B), demonstrating that NAMPT 
functions as a major NAD biosynthetic enzyme in adipose tissues.  This dramatic 
reduction in NAD levels did not seem to affect the gross structure and development of 
adipose tissue.  Mean adipocyte diameter, and body weight and body composition in 
ANKO mice were not significantly different from those in the control Namptflox/flox mice 
(Figures S1A-C).  However, we found that plasma eNAMPT levels significantly 
decreased by 30-40% in both fed and fasted conditions in ANKO females compared to 
those in control Namptflox/flox mice (Figure 1C), demonstrating that adipose tissue 
significantly contributes to the production of circulating eNAMPT in female mice.  
Contrarily, ANKO male mice did not show such decreases in plasma eNAMPT levels 
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(data not shown).  These results are consistent with the previously reported finding that 
Nampt-deficient heterozygous females exhibit a reduction in plasma eNAMPT levels, 
whereas Nampt-deficient heterozygous males do not 6.  Interestingly, while other tissues 
such as the liver and skeletal muscle did not show any change in NAD levels (Figure 1B), 
there were a couple of tissues that showed moderate but significant decreases in NAD 
levels in ANKO females.  For example, the hypothalamus, but not the hippocampus, 
showed a significant decrease in NAD levels in ANKO mice compared to controls 
(Figure 1D).  mRNA expression levels of Nampt and other NAD biosynthetic enzymes 
showed no decrease in ANKO hypothalami (Figure S1D), indicating that the reduction in 
NAD levels detected in ANKO hypothalami was not due to intrinsic defects in their NAD 
biosynthetic machineries.  Consistently, mRNA expression of Ox2r, a SIRT1 target gene 
in the brain, was also significantly decreased in hypothalamus of ANKO females, but not 
in hippocampus (Figure 1E), suggesting that NAD-dependent SIRT1 activity is lower in 
female ANKO hypothalamus.  Taken together, these results demonstrate that the adipose 
tissue-specific deficiency of NAMPT causes the reduction in NAD levels not only in 
WAT and BAT but also in the hypothalamus where the NAD biosynthetic machineries are 
intact. 
 
ANKO female mice show severe impairments in insulin sensitivity and glucose-
stimulated insulin secretion 
We found that ANKO female mice had higher blood glucose levels than control 
Namptflox/flox mice in both fed and fasted conditions (Figure 2A).  ANKO females also 
showed severe hyperinsulinemia compared to Namptflox/flox and adiponectin-Cre females 
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in the fed condition (Figure 2B).  Intraperitoneal glucose tolerance tests (IPGTTs) 
demonstrated that ANKO females had impaired glucose tolerance (Figure 2C).  During 
IPGTTs, ANKO females also showed significant hyperinsulinemia compared to control 
Namptflox/flox mice (Figure 2D, left panel).  With this, ANKO females were able to 
enhance insulin secretion only ~2-fold in response to glucose, whereas control 
Namptflox/flox mice showed ~5-fold increase in glucose-stimulated insulin secretion 
(Figure 2D, right panel), suggesting that glucose-stimulated insulin secretion is seriously 
hampered in ANKO females.  Because pancreatic islets in ANKO females looked normal 
compared to those in control Namptflox/flox females (Figure 2E), this defect of β cell 
responsiveness to glucose in ANKO females is likely not due to structural defects in 
pancreatic islets.  Insulin tolerance tests (ITTs) demonstrated that ANKO females also 
developed severe insulin resistance (Figure 2F).  HOMA-IR values, calculated from 
fasting glucose and insulin levels, also confirmed insulin resistance in ANKO females 
(ANKO 4.76±0.82, Namptflox/flox 0.70±0.15).  Different from these ANKO females, 
ANKO male mice did not show any obvious metabolic defects, except for moderate 
increases in insulin levels in fed and fasted conditions (Figures S2A-E).  This remarkable 
sex difference in ANKO mice is consistent with that previously observed in Nampt+/- 
mice 6.  Given that Nampt+/- females also display reduced plasma eNAMPT levels and 
impaired β cell function, we expected to see lower NAD levels in pancreatic β cells of 
female ANKO compared to control Namptflox/flox mice, but it was not the case (date not 
shown).   
Considering that hypothalamus also plays a critical role in glucose homeostasis 
by regulating pancreatic β cell function, it is likely that the adipose tissue-specific 
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deficiency of NAMPT independently affects both insulin secretion and action, resulting 
in complex combinatory phenotypes in glucose metabolism in ANKO females.  Indeed, 
female ANKO mice exhibit induction of adipose tissue inflammation marked by 
increased macrophage infiltration which could blunt insulin signaling in peripheral 
tissues by increasing secretion of pro-inflammatory cytokines from adipose tissues 15.  
Gene expression for markers of M1-like macrophages that secrete a characteristic 
signature of pro-inflammatory cytokines such as TNFα and IL-6 were increased, whereas 
those of M2-like macrophages that secrete anti-inflammatory cytokines such as IL-10 and 
IL-1 were decreased in female ANKO compared to control Namptflox/flox mice even under 
regular diet condition (Figure S4A).  Consistently, the macrophage population was more 
polarized to type M1 in visceral adipose tissue in female ANKO mice compared to 
female Namptflox/flox mice.  ANKO females displayed an increase in the relative 
proportion of adipose CD11b+ CD11c+ pro-inflammatory M1 macrophages (16.1%), but a 
decrease of adipose CD11b+ CD11c- anti-inflammatory M2 macrophages (56.6%), 
compared to WT (M1; 7.39%, M2; 70.2%) (Figure S4B).  These data indicate that female 
ANKO mice show severe insulin resistance and impaired glucose-stimulated insulin 
secretion due to the defects in multiple organs including adipose tissues and the 
hypothalamus.   
 
Treatment with NMN restores normal responsiveness of pancreatic β  cells to glucose 
and improves insulin sensitivity in ANKO female mice 
NMN is the product of the NAMPT enzymatic reaction and a key NAD intermediate in 
mammals.  It has been demonstrated that systemic administration of NMN is able to 
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enhance NAD biosynthesis in vivo and dramatically improve metabolic complications in 
different genetic and disease models in which NAMPT-mediated NAD biosynthesis is 
seriously compromised 6,14,16.  Therefore, we anticipated that NMN administration might 
be able to ameliorate the metabolic defects in ANKO female mice.  We administered 
NMN once a day at the dose of 500 mg/kg body weight/day for up to four weeks to a 
cohort of ANKO female mice.  As a control, we injected PBS into another cohort of 
ANKO female mice and control Namptflox/flox mice. 
 Four-week NMN treatment increased NAD levels in the WAT and BAT of 
ANKO females (Figure 3SA), although they did not reach the levels detected in control 
Namptflox/flox tissues (Figure 1B).  In accordance with these NAD increases in WAT and 
BAT, fed glucose and insulin levels decreased considerably in NMN-treated ANKO 
females (Figures 3A and B).  However, results from IPGTTs showed that the 
improvement of glucose tolerance in NMN-treated ANKO females was minimal 
compared to that in PBS-treated ANKO females (Figure 3C).  During IPGTTs, the 
absolute insulin levels in response to glucose were significantly lower in NMN-treated 
ANKO females compared to those in PBS-treated ANKO females (Figure 3D, left panel).  
Importantly, the fold increase in glucose-stimulated insulin secretion was completely 
restored in NMN-treated ANKO females to the level observed in control Namptflox/flox 
mice (Figures 3D and 2D, right panels), suggesting that the responsiveness of pancreatic 
β cells to glucose was fully recovered by NMN treatment.  On the other hand, results 
from ITTs showed that NMN-treated ANKO mice still had insulin resistance, although 
there was a significant improvement in insulin sensitivity compared to PBS-treated 
ANKO females (Figure 3E).  HOMA-IR values also confirmed this trend (PBS-treated 
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ANKO 5.38±0.76, NMN-treated ANKO 2.25±0.41, PBS-treated Namptflox/flox 0.97±0.10).  
It seemed that in NMN-treated ANKO females, β cell function to secrete insulin in 
response to glucose was fully restored by NMN, whereas the restoration of WAT and 
BAT functions might only be partial.  Indeed, we found that the levels of leptin, 
manufactured primarily in adipose tissues, were not fully restored in NMN-treated 
ANKO females (Figure 3F).  In addition, according to gene expression profiles, M1 
macrophages as well as M2 macrophages are increased in NMN-treated ANKO mice 
(Figure S4D), indicating that NMN administration did not fully restore the function of 
adipose tissues in female ANKO mice.  These data could raise the possibility that 
improvement of β cell function sensing glucose and in turn secreting insulin could be 
separated from the partial restoration of WAT and BAT function by NMN treatment in 
female ANKO.  Taken together, these results from NMN treatment strongly suggest that 
defects in NAD biosynthesis detected in adipose tissue and hypothalamus, which are 
caused by the adipose tissue-specific deficiency of NAMPT, essentially contribute to the 
impairments in insulin sensitivity and insulin secretion in ANKO female mice. 
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DISCUSSION 
In our previous study in chapter 3, we clearly demonstrated that the secretion and the 
enzymatic activity of eNAMPT are regulated by SIRT1-dependent deacetylation in 
adipocytes in response to nutrient availability.  Here we demonstrated why adipose tissue 
secretes eNAMPT into blood circulation using this sophisticated mechanism. We have 
obtained important clues as to the function of eNAMPT using adipose tissue-specific 
Nampt knockout (ANKO) mice.  ANKO females, but not males, show significant 
decreases in plasma eNAMPT levels.  A surprising finding is that the adipose tissue-
specific deficiency of NAMPT causes significant reduction in NAD levels not only in 
WAT and BAT but also in the hypothalamus.  Because the hypothalamus in ANKO 
females does not have any obvious defects in the NAD biosynthetic machineries, the 
reduction in NAD levels detected in this remote tissue is likely attributed to the NAMPT 
deficiency in adipose tissue.  Furthermore, the defect appears to be very specific to 
hypothalamus because other tissues and organs, including the liver, skeletal muscle, and 
the hippocampus that is located close to the hypothalamus, do not show any reduction in 
NAD.  Female ANKO mice exhibit severely impaired glucose tolerance and glucose-
stimulated insulin secretion, even though they have hyperinsulinemia.  Although where 
exactly NMN is synthesized by eNAMPT still remains a critical question, these results 
from ANKO mice open a novel paradigm for the systemic regulation of NAD 
biosynthesis and metabolism through the regulation of the secretion and enzymatic 
activity of eNAMPT from adipose tissue. 
The results from ANKO mice reveal a surprising connection between adipose 
tissue and another remote tissue, the hypothalamus.  The fact that the adipose tissue-
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specific deficiency of NAMPT causes such severe metabolic complications is 
remarkable, supporting the importance of NAMPT-mediated NAD biosynthesis in 
adipose tissue for the systemic regulation of glucose metabolism.  It is possible that the 
severe insulin resistance observed in ANKO females might be caused by functional 
defects in multiple tissues, particularly the hypothalamus and adipose tissues, both of 
which show significant reduction in NAD levels.  For example, the hypothalamus 
regulates glucose metabolism through the melanocortin system which senses systemic 
hormonal and nutritional changes and in turn governs appetite and energy expenditure via 
leptin, ghrelin and Agouti-related protein (AgRP) 17,18.  The hypothalamus also directly 
controls insulin secretion from pancreatic β cell by signaling through the autonomous 
nervous system and hypothalamic hormones 19-21.  Considering those, it is likely that 
decreased NAD in the hypothalamus could cause a defect in hypothalamic function for 
the regulation of glucose homeostasis, contributing to insulin resistance.  In addition, 
inflammation in adipose tissues, induced by infiltration of large numbers of macrophages 
as shown in female ANKO mice, has a key role in systemic insulin resistance, impaired 
glucose tolerance and the development of metabolic syndrome and type 2 diabetes 15.  
Given that reducing SIRT1 expression in lean animals is sufficient to activate NF-κB, a 
key protein upregulated in immune response, resulting in macrophage infiltration in 
adipose tissues similar to that seen in obesity 22, this female ANKO phenotype could also 
be at least partly due to inactivation of SIRT1 caused by reduction of NAD levels in 
adipose tissues since NAD is required for SIRT1 deacetylase reaction.  However, the 
hypothalamus might also remotely control macrophage infiltration in adipose tissue.  
Indeed, loss of autophagy only in POMC neurons in the hypothalamus has been shown to 
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cause an increase in the proportion of M1 macrophages in adipose tissue 23.    
Interestingly, NMN treatment almost completely restores the defect in glucose-
stimulated insulin secretion in ANKO female mice with a significant improvement of 
hyperinsulinemia, but only partially improves glucose tolerance and insulin sensitivity in 
these animals.  For instance, HOMA-IR indices calculated for PBS-treated Namptflox/flox, 
PBS-treated ANKO, and NMN-treated ANKO mice are 0.97, 5.38, and 2.25, respectively, 
showing approximately a 60% improvement in insulin sensitivity by NMN treatment.  
This partial improvement in insulin sensitivity appears to be due to the incomplete 
restoration of NAD levels in adipose tissue after NMN treatment.  Consistent with this 
notion, plasma leptin levels as well as adipose tissue macrophages in NMN-treated 
ANKO mice are not fully brought back to the levels in control Namptflox/flox mice.  One 
likely explanation is that adipose tissue has higher NAD turnover compared to other 
tissues so that more frequent or continuous NMN administration might be necessary to 
achieve full NAD restoration. Further investigation will be required to flesh out the 
detailed mechanism of the severe insulin resistance caused by the deficiency of NAMPT 
in adipose tissue. 
 eNAMPT produces NMN in blood, which is then distributed to specific remote 
tissues like the hypothalamus and influences its function.  Considering that plasma 
eNAMPT levels are significantly reduced in ANKO mice, one plausible explanation to 
describe the ANKO phenotype is that lower levels of eNAMPT result in lower NMN 
production in blood, which then limits the NMN distributed to tissues throughout the 
body.  Insufficient NMN could disturb the regular function of remote tissues, including 
the hypothalamus.   A recent study argues against this possibility, claiming that NAMPT 
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is unable to synthesize NMN in blood circulation 24.  However, caution is required to 
extrapolate the results from this study to the in vivo environment for the following 
reasons.  First, this study used bacterially produced recombinant NAMPT in all assays.  
As shown in our present study, bacterially produced recombinant NAMPT carries 
acetylated lysines similar to iNAMPT, but completely different from eNAMPT.  Second, 
the equilibrium of the NAMPT reaction must be shifted constantly to the production of 
NMN in blood circulation because NMN is swiftly transported into tissues, as previously 
reported 16, suggesting that detecting low steady-state concentrations of NAMPT 
substrates in plasma does not necessarily mean that NAMPT is unable to synthesize 
NMN in the blood.  Indeed, this study reports that when adding NAMPT and its 
substrates to blood, NMN biosynthesis can clearly occur.  Therefore, it is critically 
important to examine the in vivo kinetics of NMN biosynthesis in both tissues and blood 
circulation, which is still a significant technical challenge.  The study to address this key 
question is currently underway. 
Our previous findings that adipose tissue actively regulates the secretion and 
enzymatic activity of eNAMPT in an NAD/SIRT1-dependent manner suggest the 
possibility that adipose tissue functions as a critical determinant for the spatial and 
temporal coordination of NAD biosynthesis throughout the body.  Our present findings in 
chapter 4 show that ANKO females, having lower plasma eNAMPT levels compared to 
Namptflox/flox mice, display significant reduction of NAD levels in the hypothalamus.  
This finding supports the idea that the systemic coordination of NAD biosynthesis via 
eNAMPT might play an important role in orchestrating metabolic responses in multiple 
tissues and maintaining metabolic homeostasis against nutritional and environmental 
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perturbations.  However, there are a couple of questions that remain to be investigated.  
For instance, we still do not fully understand exactly where eNAMPT-mediated NAD 
biosynthesis occurs.  The detailed molecular mechanism underlying the impaired glucose 
tolerance and attenuated β cells function in female ANKO mice is also still unclear.   
Further studies may soon give us a more complete understanding of the mechanism by 
which eNAMPT-mediated NAD biosynthesis regulates glucose homeostasis, and thus 
give us the potential to design effective therapies for metabolic diseases such as type 2 
diabetes.    
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EXPERIMENTAL PROCEDURES 
Generation of ANKO mice 
Namptflox/flox mice and Adiponectin-Cre mice were generated as described previously and 
generously provided to us 25,26.  Adiponectin-Cre mice were mated with Namptflox/flox 
mice, and cohorts were established by mating F1 Namptflox/+;Cre  to Namptflox/flox mice. 
Namptflox/flox;Cre and Namptflox/flox;+ were considered as ANKO and WT, respectively. 
 
Detection of intracellular NAMPT in tissues, and of extracelluar NAMPT in plasma 
Mice fed ad libitum were euthanized by carbon dioxide asphyxiation. Organs were 
immediately collected, homogenized in 1X Laemmli’s sample buffer, and boiled for 5 
minutes. Samples were then centrifuged at 16000g and protein concentrations of 
supernatant were measured by the Bradford assay (Biorad, CA). Plasma from mice fed ad 
libitum or fasted for 48 hours was collected by centrifuging blood at 3200g for 5 minutes 
at 4°C and immediately boiled for 5 minutes in 1X Laemmli’s sample buffer. Tissue 
extracts and plasma samples were analyzed by Western blotting with anti-NAMPT 
(Bethyl Laboratories, TX) or anti-ACTIN (Sigma, MO) antibodies.   
 
NAD+ measurements  
Frozen tissues were extracted in perchloric acid and neutralized in K2CO3 on ice as 
described previously (Ramsey et al., Science, 324:651). NAD+ levels were determined 
using an HPLC system (Shimadzu, Japan) with a Supelco LC-18-T column (15 cm x 4.6 
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cm; Sigma, MO). The HPLC was run at a flow rate of 1 ml/min with 100% buffer A (50 
mM phosphate buffer, pH 7.4) from 0-5 min, a linear gradient to 95% buffer A /5% buffer 
B (100% methanol) from 5-6 min, 95% buffer A /5% buffer B from 6-11 min, a linear 
gradient to 85% buffer A /15% buffer B from 11-13 min, 85% buffer A /15% buffer B 
from 13-23 min, and a linear gradient to 100% buffer A from 23-24 min. NAD+ is eluted 
at about 11 min. NAD+ levels were quantitated based on the peak area compared to a 
standard curve and normalized to the weight of the frozen tissue or to the number of 
primary islets.  
 
RNA isolation and analysis 
Total RNA from WAT and BAT was isolated using an RNeasy lipid tissue mini-kit 
(QIAGEN, CA). Total RNA from the other tissues was isolated using RNeasy mini-kit 
(QIAGEN, CA). cDNA was synthesized using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA) with random primers. Quantitative real-time 
PCR was performed using the 7500 Fast Real-Time PCR system (Applied Biosystems, 




Mice were maintained on a standard diet (PicoLab 5053 Rodent Diet 20 [Lab Diets, 
St.Louis, MO, USA]) with free access to food and water under a 12 hour light/ dark cycle 
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at constant temperature (22°C). For IPGTT experiments, mice were fasted for 16 hours, 
and 50% dextrose (2g/kg body weight) was injected intraperitoneally. Blood was 
collected from the tail vein at 0, 15, 30, 60, and 120 minutes. Blood glucose levels were 
determined using an Accu-Chek II glucometer (Roche Diagnostics), and plasma insulin 
levels were determined using the Singulex Erenna immunoassay system at the 
Washington University Core Laboratory for Clinical Studies. For ITT experiments, mice 
were fasted for 4 hours before they were injected with human insulin (0.75U/kg body 
weight; Lilly). Blood glucose levels were measured at 0, 15, 30, 45, and 60 minutes after 
insulin injections. Lipid, cholesterol, and triglyceride levels were measured using 
reagents from Thermo Electron Corporation (Waltham, WA), while non-esterified free 
fatty acid levels were measured using reagents from Wako (Richmond, VA) at the 
Washington University Animal Model Research Core associated with the Nutrition 
Obesity Research Center (NORC) and the Diabetes Research and Training Center 
(DRTC). Plasma leptin levels were measured using a mouse leptin ELISA kit (Milipore, 
MA) at the Washington University Core Laboratory for Clinical Studies. For body 
composition analysis, mice were subjected to magnetic resonance imaging (EchoMRI, 
TX).  For synchronization of female estrus cycle, female mice were exposed to bedding 
from male cages for 3 days.  Synchronized females were used in all mouse experiments. 
Statistical analysis 
Differences between two groups were assessed using the Student’s t test. Comparisons 
among several groups were performed using one-way ANOVA with the Fisher’s LSD 
post-hoc test. p values less than 0.05 were considered statistically significant. 
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FIGURE LEGENDS 
Figure 1. ANKO mice have lower plasma eNAMPT and NAD+ levels in the 
hypothalamus and adipose tissue.  
(A)  iNAMPT levels in visceral WAT, subcutaneous WAT, BAT, brain, liver, and 
muscle from 2-month-old female Namptflox/flox and ANKO mice.  
(B)  Plasma eNAMPT levels from 5-6-month-old female Namptflox/flox and ANKO 
mice. Plasma was collected from mice fed or fasted for 48 hours. Bottom panels 
represent eNAMPT levels from each genotype normalized to Namptflox/flox (n = 8-
10).  
(C)  Tissue NAD+ levels in visceral WAT, subcutaneous WAT, BAT, liver, and skeletal 
muscle from 3-4-month-old female Namptflox/flox and ANKO mice (n = 4-8). 
(D)  Tissue NAD+ levels in hypothalamus and hippocampus from 3-4-month-old 
female Namptflox/flox and ANKO mice (n = 4-8), and in pancreatic islet NAD+ 
levels from 5-6-month-old female Namptflox/flox and ANKO mice. 
(E)  Quantitative RT-PCR results for Ox2r mRNA expression in hypothalamus of 3-4-
month-old fed female Namptflox/flox and ANKO mice (n = 4). 
Data were analyzed by the Student’s t test.  All values are presented as mean ± SEM. 
*p < 0.05; **p < 0.01; ***p<0.001 
 
Figure 2.  ANKO mice have impaired glucose metabolism and hyperinsulinemia. 
(A)  Fed or fasted (48 hours) plasma glucose levels in 3-4-month-old female 
Namptflox/flox and ANKO mice (n = 7-9). 
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(B)  Fed plasma insulin levels in 3-4-month-old female Namptflox/flox, ANKO, and 
adiponectin-Cre mice (n = 5-10). 
(C)  Glucose tolerance in 3-4-month-old female Namptflox/flox (dotted line) and ANKO 
(solid line) mice (n = 4-5). The area under the curve (AUC) is presented next to 
the glucose tolerance curves.  
(D)  Plasma insulin levels in 3-4-month-old female Namptflox/flox and ANKO mice 
during IPGTT.  The right panel represents insulin normalized to the basal level at 
0 min.  
(E)  Representative hematoxylin and eosin staining of paraffin-embedded pancreas 
section from 3-4-month-old fed Namptflox/flox and ANKO mice. 
(F)  Insulin tolerance in 3-4-month-old female Namptflox/flox (dotted line) and ANKO 
(solid line) mice (n = 6).   
Data were analyzed by the Student’s t test and one-way ANOVA with the Fisher’s 
LSD post-hoc test. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; 
***p < 0.001. 
 
Figure 3.  NMN administration improves hyperinsulinemia and glucose metabolism 
in 7-8 month-old female ANKO mice compared to wild-type. 
(A)  Fed plasma glucose levels after PBS or NMN treatment (n = 9). 
(B)  Fed plasma insulin levels after PBS or NMN treatment (n = 9).  
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(C)  Glucose tolerance after PBS (solid line) or NMN (dotted line) treatment (n = 9) 
in female ANKO mice. The area under the curve (AUC) is presented next to the 
glucose tolerance curves.  
(D)  Plasma insulin levels during IPGTT.  The right panel represents insulin 
normalized to the basal level at 0 min.  
(E)  Insulin tolerance test after PBS (solid line) or NMN (dotted line) treatment (n = 
9) in female ANKO mice. 
(F)  Plasma leptin levels after PBS or NMN treatment. 
NMN (500 mg/kg body weight/day) was administered for 4 weeks. ITTs were 
conducted several days before IPGTTs.  Data were analyzed by the Student’s t test 
and one-way ANOVA with the Fisher’s LSD post-hoc test.  All values are presented 
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                                                                                                                 Figure S1 
Supplementary Figure 1. Female ANKO mice have normal adipose tissue 
morphology and gene expression profiles in the hypothalamus. 
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(A)  Representative hematoxylin and eosin staining of paraffin-embedded visceral 
WAT section from 3-4-month-old fed female WT and ANKO mice.  The right 
panel shows the mean adipocyte diameter from 3-4-month-old fed female WT and 
ANKO mice (n=2). 
(B)  Body weights of 4-month-old female WT and ANKO mice on a standard diet (n 
= 9-11). 
(C)  Body composition analysis of 4-month-old female WT and ANKO mice on a 
standard diet (n= 2-4). 
(D)  Quantitative RT-PCR results for genes representative of NAD+ biosynthesis in 
hypothalamus of 3-4-month-old fed female WT and ANKO mice (n = 4). 
 Data were analyzed by the Student’s t test.  All values are presented as mean ± SEM. 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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                                                                                                                 Figure S2 
 
Supplementary Figure 2. Male ANKO mice have normal glucose metabolism and 
insulin secretion compared to wild type.  
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(A)  Fed or fasted (48 hours) plasma glucose levels in 3-4-month-old male 
Namptflox/flox and ANKO mice (n = 7). 
(B)  Fed plasma insulin levels in 3-4-month-old male Namptflox/flox and ANKO mice 
(n = 6). 
(C) Glucose tolerance in 3-4-month-old male WT and ANKO mice (n = 6-7). The 
area under the curve (AUC) is presented next to the glucose tolerance curves.  
(D)  Plasma insulin levels in 3-4-month-old male WT and ANKO mice during 
IPGTT.  The right panel represents insulin normalized to the basal level at 0 min. 
(E)  Insulin tolerance in 3-4-month-old male WT and ANKO (n = 6-7). 
Data were analyzed by the Student’s t test and one-way ANOVA with the Fisher’s 
LSD post-hoc test. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; 
***p < 0.001. 
 
  139 
                                                                                                                 Figure S3 
 
Supplementary Figure 3.  Female ANKO mice exhibit increased macrophage 
infiltration polarized to M1 in adipose tissue compared to wild type. 
(A)   Quantitative RT-PCR results for genes representative of M1 and M2 
macrophages in adipose tissue of 3-4-month-old fed female Namptflox/flox and 
ANKO mice (n = 2-4). 
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(B)   Adipose tissue macrophages (ATM) from the stromal vascular fraction analyzed 
by flow cytometry.  The percentage of Cd11c+ (upper right quadrant; M1) and 
Cd11c- (upper left quadrant; M2) cells within the Cd11b+ ATM population is 
shown.  
Data were analyzed by the Student’s t test.  All values are presented as mean ± SEM. 
*p < 0.05; **p < 0.01. 
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                                                                                                                 Figure 4S 
 
Supplementary Figure 4. NMN administration to ANKO mice does not fully restore 
NAD+ levels in adipose tissue to that of WT and does not significantly alter adipose 
tissue macrophages  
(A)  Tissue NAD+ levels in visceral WAT and BAT from 7-8-month-old female ANKO 
mice after PBS or NMN treatment for 4 weeks (n = 3). 
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(B)  Quantitative RT-PCR results for genes representative of M1 and M2 
macrophages in adipose tissue of 7-8 month old female ANKO mice after PBS or 
NMN treatment for 4 weeks (n = 3). 
Data were analyzed by the Student’s t test.  All values are presented as mean ± SEM. 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES  
Adipocyte size measurement 
10-50 mg of white adipose tissue was fixed for at least 30 days in a solution containing 
0.2 M Osmium Tetroxide and 50 mM Collidine-HCL buffer. After fixation, samples were 
collected onto a 10 micron screen and then washed with saline for 24 hours. After 
washing, samples were again collected onto a 10 micron screen and then incubated for 3-
4 days in 8 M Urea in saline to further dissociate the tissue. After urea treatment, samples 
were filtered through a 250 micron screen and collected onto a 10 micron screen. Free, 
fixed adipocytes were removed from the filter and stored in saline (0.154 M NaCl with 
0.01% Triton) at 4°C until Multisizer analysis. Analysis was performed at the Washington 
University Nutrition Obesity Research Center (NORC).  For the analysis, samples were 
processed on a Beckman MultisizerTM 3 Coulter Counter (Beckman Coulter, CA).  For 
each sizing run, microsphere beads in sizes 50, 100, and 150 mm were run to confirm 
proper calibration. Data was analyzed using the Multisizer 3 software (Beckman Coulter, 
CA). 
 
Isolation of stromal vascular cells and flow cytometry.  
The epididymal fat pad was removed from mice and minced into small pieces (~1 mm).  
The minced tissue was transferred to tubes containing 30 µg/ml Liberase TM (Roche, 
Germany) and 1.5% BSA in KRH buffer (4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 
118 mM NaCl, 20 mM HEPES) and shaken vigorously at 37°C for 20~30 min.  The 
digested tissue was strained through a 250 µM nylon mesh and centrifuged at 100g for 5 
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min.  The pellet was washed twice with KRH buffer + 1.5% BSA, incubated in ACK lysis 
buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) to remove erythrocytes, and 
finally resuspended in PBS supplemented with 1% BSA and 2 mM EDTA.  
The isolated stromal vascular cells were blocked with mouse BD Fc BlockTM 
(BD Pharmingen, CA) for 15 min and stained with antibodies to CD45, CD11b, and 
CD11c (BD Pharmingen, CA) to identify M1 (CD11b+, CD11c+) and M2 (CD11b+, 
CD11c-) macrophage populations.  7-AAD (BD Pharmingen, CA) was used to exclude 
dead cells.  FACS data was collected and analyzed with a FACSCantoII flow cytometer 























 In this thesis work, I provided biochemical and physiological evidence that shows 
how NAMPT is regulated in response to both alterations in nutrient conditions and the 
aging process in cellular and systemic levels, and how glucose homeostasis is affected 
through these regulations.  First, iNAMPT levels and NAMPT-mediated NAD+ 
biosynthesis are decreased in metabolically active tissues, specifically adipose tissue and 
liver, under high fat diet and with age contributing to the pathogenesis of type 2 diabetes.  
Second, administration of NMN, an enzymatic product of NAMPT, ameliorated impaired 
glucose tolerance in high fat diet- or age- induced type 2 diabetic mice by restoring 
normal NAD+ levels and in turn enhancing SIRT1 activity.  This resulted in either 
improved insulin sensitivity or insulin secretion.  Third, SIRT1 deacetylates iNAMPT, 
which causes increases in both eNAMPT secretion and its enzymatic activity in adipose 
tissue, when nutrient availability is limited.  Fourth, knocking out Nampt specifically in 
mouse adipose tissue displays a phenotype of impaired glucose tolerance and reduced 
glucose-stimulated insulin secretion in pancreatic β cells. This is presumably due to 
lower NAD+ levels in remote metabolic tissues such as the hypothalamus, and these 
phenotypes can be corrected by the administration of NMN.  
The findings presented here provide the first evidence that NAMPT protein levels 
and NAMPT-mediated NAD+ biosynthesis is compromised by high fat diet and aging, 
contributing to the pathogenesis of type 2 diabetes.  Additionally, we present the first 
proof of concept that promoting NAD+ biosynthesis by administration of NMN, a key 
NAD+ intermediate, can be an effective intervention to treat the pathophysiology of diet- 
and age- induced type 2 diabetes.  We also demonstrated that eNAMPT secretion is 
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positively regulated by SIRT1 in response to nutrient availability in adipose tissues.  By 
deacetylating K53 on NAMPT, SIRT1 controls not only eNAMPT secretion from 
adipocytes but also its enzymatic activity, comprising a new positive feed back loop.  
Furthermore, by using female adipose tissue-specific Nampt knock out (ANKO) mice, 
we revealed that NAMPT in adipose tissue contributes to the maintenance of whole body 
glucose homeostasis regulating remote tissues through its enzymatic activity and 
presumably also through its secretion.  In this chapter, I will further discuss my findings 
of the function and regulation of eNAMPT in the context of the current knowledge.  I 
will also discuss the questions that still remain or have newly arisen from my thesis work.               
 
Do NAMPT and SIRT1 compose a new feedback loop?   
The biological significance of the NAD+ biosynthetic pathway in the regulation of 
the enzymatic activity of Sirtuins has been highlighted.  In particular, NAMPT, the rate-
limiting enzyme in the mammalian NAD+ biosynthetic pathway, has recently been shown 
to have important roles related to sirtuin biology, metabolism, cancer, and the immune 
response.   However, how NAMPT itself and NAMPT-mediated NAD+ biosynthesis are 
regulated has not been comprehensively studied yet.  Recently, it has been reported that 
NAMPT and NAD+ levels display circadian oscillations that are regulated by the core 
clock machinery in mice 28,29.  This genetic mechanism involves the heterodimeric 
CLOCK/BMAL1 complex, a key structure of circadian transcription factors that control 
the circadian oscillation of NAMPT and its metabolite NAD+ levels by inducing Nampt 
transcription.  This loop is closed by feedback from the NAD+-dependent deacetylase 
SIRT1.  SIRT1 is a component of the CLOCK/BMAL1 transcription complexes and acts 
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as a negative transcriptional regulator, thus comprising a novel circadian clock feedback 
loop involving NAMPT/NAD+ and SIRT1/CLOCK/BMAL1.  
 Nampt transcription also seems to be positively regulated by SIRT1 depending on 
the nutrient condition or cell type.  Tao et al., have demonstrated that both Nampt gene 
expression and NAMPT-dependent NAD+ biosynthesis in hepatocytes are controlled by 
Forkhead box protein Os (FOXOs), whose activity is increased by SIRT1 through their 
deacetylation 30,31.  Combinatorially with SIRT1, FOXOs protect against fatty liver 
disease by increasing Nampt transcription, and in turn NAD+ biosynthesis in hepatocytes 
30.  In human colorectal cancer cells, SIRT1 enhances Nampt transcription by stabilizing 
c-MYC, which binds to a region encompassing the noncanonical E-box in the Nampt 
promoter, resulting in suppression of senescence and apoptosis in cells, and presumably 
contributing to the development and maintenance of tumors in the context of deregulated 
c-MYC  32.  
In chapter 3, we proposed a new mechanism in which NAMPT is also regulated 
by SIRT1 on a post-translational level.  We found that iNAMPT is acetylated in adipose 
tissue and that the acetylation level of iNAMPT is decreased during fasting, partly by 
SIRT1.   By deacetylating lysine 53 on iNAMPT, SIRT1 increases both enzymatic 
activity and secretion of eNAMPT from adipocytes.  NAMPT is undoubtedly an 
important regulator of Sirtuins, including NAD+-dependent SIRT1, because of its role in 
converting Nicotinamide into NMN, a crucial NAD+ precursor in mammals.  Considering 
this, an increase in eNAMPT secretion by SIRT1 from adipose tissue could enhance 
NAD+ biosynthesis systemically, resulting in activation of Sirtuins in remote tissues, 
which generates a new positive feedback loop involving NAMPT/NAD+ and SIRT1. 
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How is eNAMPT secreted? 
 Soluble secretory proteins typically contain N-terminal signal peptides that direct 
them to the translocation appratus of the endoplasmic reticulum (ER).  Following 
vesicular transport from the ER via the Golgi to the cell surface, lumenal proteins are 
released into the extracellular space by fusion of Golgi-derived secretory vesicles with 
the plasma membrane.  This pathway of protein export from eukaryotic cells is known as 
the classical, or ER/Golgi-dependent secretory pathway.  However, Nampt does not 
possess an appropriate cleavable signal sequence 2, and the mechanism that mediates the 
secretion of eNAMPT from adipocytes has remained poorly understood.  We have 
previously found though that eNAMPT is not released simply because of cell lysis or cell 
death, but that it is actively secreted from adipocytes 3.  In this study, we established 
HIB-1B cell lines constitutively expressing FLAG-tagged Nampt or FLAG-tagged 
preprolactin (Ppl), which is secreted through the ER/Golgi secretory system.  When these 
cells were treated with brefeldin A, an inhibitor of protein transport from the ER to the 
Golgi, which led to protein accumulating inside of the ER, the secretion of eNAMPT was 
not affected while Ppl secretion was completely inhibited 3.  It has been proposed that 
many other proteins including Fibroblast growth factor 1 (FGF-1), and FGF-2, 
Thioredoxin, Interleukin 1α (Il1α), and Il1β, gelectin-1 and -3, and High Mobility Group 
Protein 1 (HMGB1), are exported by a mechanism that is independent of the classical 
secretory pathway, and many of them are known to directly accumulate at specific spots 
and form microvesicles in the cells 4, indicating that NAMPT secretion might be secreted 
through an unconventional microvesicle-dependent protein secretion pathway.  Tanaka et 
al. clearly ruled out this possibility through subcellular fractionation analysis showing 
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that NAMPT is exclusively localized in cytoplasm, but not in the membrane or in 
vesicles 2.  Taken together, these data suggested that eNAMPT is secreted through a non-
classical secretory pathway independent of the ER/Golgi or microvesicle secretory 
system.  
 In an effort to elucidate a more detailed secretion mechanism of eNAMPT, I 
proposed that acetylation status is an important factor to regulate eNAMPT secretion 
from adipocytes.  Through mass-spectrometry analysis, I observed that the acetylation 
status of iNAMPT was different from that of eNAMPT.  Five acetylation sites were 
found on iNAMPT in mammalian cells, while only 4 out of 5 acetylation sites that were 
found on iNAMPT were deacetylated on eNAMPT, implying that acetylation condition 
differentiates eNAMPT from iNAMPT.   We also found that the levels of acetylation on 
iNAMPT in adipocytes were decreased in adipocytes of fasted mice compared to an ad 
lib condition, but plasma eNAMPT levels were increased in the same conditions.  
Interestingly, plasma eNAMPT levels were unchanged in fasted Sirt1 KO mice, 
suggesting that SIRT1 is involved in deacetylating iNAMPT and increasing eNAMPT 
secretion into plasma in response to changes in nutritional conditions.  Through in vitro 
biochemistry experiments using differentiated brown and white adipocytes and HEK293 
cells, we also have confirmed that SIRT1 induces eNAMPT secretion by deacetylating 
lysine 53 on iNAMPT in adipocytes.  Taken together, we conclude that acetylated 
iNAMPT stays in the cells while deacetylated iNAMPT, by SIRT1 during fasting, is 
predisposed to an undefined secretory mechanism and transmitted out of adipocytes.  
 Unfortunately, the detailed molecular mechanism of eNAMPT secretion upon 
acetylation is still in mystery.  So far, there has been only one report showing that 
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acetylation status of the protein is involved in its secretion.  Gardella et al., showed that 
activation of monocytes results in the accumulation of HMGB1, which also lacks a 
secretory signal peptide and does not traverse the ER-Golgi system, into cytoplasmic 
vesicles that display the features of secretory lysosomes 5.  In the following study, 
Bonaldi et al, demonstrated that monocytes and macrophages increase acetylation levels 
of HMGB1 extensively upon activation with lipopolysaccharide.  This results in 
relocalization of HMGB1 to the cytosol to be secreted through a secretory lysosome, 
which is also used for other cytokines such as IL-1β and IL-18 6.  Interestingly, 
acetylation promotes the secretion of HMGB1, whereas deacetylation promotes the 
secretion of eNAMPT.  In addition, it is already well recognized that eNAMPT is 
secreted through non-classical secretory mechanism 2,3.  Based on these findings, it would 
be possible that eNAMPT secretion, dependent upon its acetylation status, requires the 
presence of specific transporters or organelles.  According to the NAMPT protein dimer 
structure, the lysine 53 acetyl groups that are deacetylated by SIRT1 are located close to 
the enzymatic core domain of the NAMPT dimer and project from NAMPT like antennas 
(Chapter 3, Figure 4b).  Therefore, the acetylated lysine 53 residues could serve as 
docking sites for binding partners responsible for sequestering iNAMPT from secretory 
machinery, and in turn, iNAMPT deacetylated by SIRT1 could be released from a 
binding partner and translocated to a particular transporter or organelle upon appropriate 
stimulation.  To clarify this hypothesis in the future, it would be interesting and also 
important to find iNAMPT binding partners by performing MS analysis of proteins that 
are co-immunoprecipitated with iNAMPT from adipocytes and analyze their roles in 
controlling eNAMPT secretion. ?
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Is adipose tissue the only source of eNAMPT?  
 It has not been studied whether adipose tissue is the only source for eNAMPT in 
mammals, or if there are other organs or tissues that are capable of releasing significant 
amounts of eNAMPT into plasma.  To answer this question, I successfully generated 
adipose tissue-specific Nampt knock out (ANKO) mice by breeding adiponectin-Cre 
mice to Namptflox/flox mice.  While ANKO mice showed almost complete knock out of 
Nampt expression in several adipose tissue depots, eNAMPT levels in plasma were only 
reduced by 30-40%, depending on nutritional condition compared to WT, indicating that 
there are other sources that supply plasma eNAMPT other than adipose tissue.  Nampt 
was originally identified from a human peripheral blood lymphocyte cDNA library as a 
presumptive cytokine 7.  In addition, its expression widely found in the immune system is 
induced by inflammatory stimuli in cells engaging in innate immunity, specifically within 
neutrophils, monocytes, and macrophages, as well as in epithelial and endothelial cells 7,8.  
Based on these findings, it has been proposed that these immune cells could be a major 
source of plasma eNAMPT.  In an effort to prove this hypothesis, Friebe and his 
colleagues have evaluated which leukocyte subpopulations account for the high 
eNAMPT production 9.  They have found that Nampt mRNA expression was higher in 
granulocytes and monocytes compared to lymphocytes, and that granulocytes released 
enzymatically active eNAMPT protein into cell culture supernatant fractions significantly 
more than other cell types 9.  These findings indicate that granulocytes may be the major 
source for plasma eNAMPT.  However, this seems not to be the case.  In Nampt knock 
out mice specifically in myeloid cell lines such as monocytes, mature macrophages, and 
granulocytes, made by using Namptflox/flox mice and lysM-Cre mice, plasma eNAMPT did 
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not change compared to Namptflox/flox control mice (M.J. Yoon, D. MacDuff, and H. W. 
Virgin, unpublished data).  A healthy typical adult has a blood volume of approximately 
4.7 to 5 liters, and the number of leukocytes is normally between 4x109 and 1.1x1010 
which makes up approximately only 1% of blood in a healthy adult.  Considering this, 
leukocytes could supply only a small fraction of plasma eNAMPT compared to other 
sources even though leukocytes secrete significant amount of eNAMPT.  
 Recent studies show that eNAMPT levels in serum are lower in patients with non-
alcoholic steatohepatitis than in patients with simple steatosis or obese healthy control 10, 
and that plasma eNAMPT levels are dramatically decreased in patients with liver 
cirrhosis 11.  This raised the possibility that hepatocytes could play an important role in 
maintaining plasma levels of eNAMPT.  In line with these two recent papers, Garten et 
al. demonstrated that eNAMPT was released from HepG2 cells as well as primary rat and 
human hepatocytes 12.  The separation of HepG2 supernatants according to molecular 
weight using size exclusion chromatography revealed that a greater amount of eNAMPT 
was present as the potentially enzymatically active dimer and a minor portion as the 
monomer, indicating that hepatocytes may release enzymatically active eNAMPT into 
the plasma as adipocytes do.  However, while adipocytes actively regulate eNAMPT 
secretion depending on nutritional condition (Chapter 3), eNAMPT secretion from 
hepatocytes seems not to be influenced by glucose, but released in a more constitutive 
fashion.  These results suggest that although both adipocytes and hepatocytes secrete 
enzymatically active eNAMPT into plasma, adipocytes possess a particular mechanism to 
sense environmental changes and control eNAMPT secretion,  
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   Even though the mechanism regulating eNAMPT secretion in hepatocytes 
differs from that in adipocytes, hepatocytes are likely able to compensate for any lack of 
function of adipocytes to secrete eNAMPT.  For example, in the fed condition, ANKO 
mice did not show abnormal protein expression of iNAMPT in any tissues, compared to 
control Namptflox/flox mice.  However, in the fasted condition, when eNAMPT secretion 
from adipocytes was increased, ANKO mice exhibited increased iNAMPT expression in 
liver, but not in muscle, which does not contain any eNAMPT secretion capacity. 
Consistent with this, fasted liver NAD+ levels increased by 30% compared to WT.  This 
implies that there might be crosstalk between the liver and adipose tissue to compensate 
for each other’s eNAMPT secretion capabilities, especially when more eNAMPT is 
required.  Our colleague, Dr. David Rudnick at Washington University in St. Louis, is 
generating Liver-specific Nampt knock out mice using Namptflox/flox and albumin-CRE 
mice.  Using them would be of great interest to compare the effects of glucose 
metabolism on eNAMPT secreted from liver to that from adipose tissue, and to examine 
if any communication exists between the two tissues that controls physiological 
requirements of eNAMPT in response to nutritional conditions.         
 
What is the function of eNAMPT, cytokine or NAD+-biosynthetic enzyme?  
eNAMPT has been suggested to possess three different activities.  First, eNampt 
was identified as a cytokine that enhances the maturation of B cell precursors in the 
presence of IL-7 and stem cell factor 7.  Second, eNampt was described as a new visceral 
fat-derived hormone named visfatin, possessing insulin-mimetic effects by directly 
binding to insulin receptor 13.  Finally, we identified eNampt to be the rate-limiting NAD+ 
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biosynthetic enzyme in mammals 14,15.  Subsequent studies have produced conflicting 
results regarding the physiological significance for the first two functions, and the lack of 
a putative receptor challenges the claim that eNAMPT is a cytokine or insulin-mimetic 
hormone.  Despite the conflicts, we have clearly demonstrated that eNAMPT exhibits 
robust NAD+ biosynthesis enzymatic activity similar to iNAMPT, and that eNAMPT 
does not exert insulin-mimetic effects in vitro or in vivo 3,15.      
Recently, one group has questioned the function of eNAMPT as a NAD+ 
biosynthetic enzyme, especially in plasma 16.  Hara et al., have claimed that eNAMPT 
cannot participate in NMN formation in plasma due to a lack of ATP, the activator of 
NAMPT, in extracellular spaces 16.  However, a significant amount of NMN was able to 
be produced when they added PRPP and ATP for the reaction in plasma.  Based on this 
result, it is possible that extracellular concentrations of ATP might rise high enough to 
support NMN synthesis under specific conditions, such as in spleen where old red blood 
cells are destroyed and recycled and in the microenvironment of damaged cells.  ATP is 
important as a source of adenosine, but also deleterious due to its intrinsic activity in the 
tumor microenvironment.  For instance, ATP itself has pro-inflammatory activity that 
modulates inflammation by triggering IL-1 maturation and release 17.  In addition, ATP 
causes the release of metalloproteases (MMP9) and induction of indoleamine oxygenase 
in dendritic cells.  Both of these activities may be very relevant for tumor progression as 
MMP9 release facilitates tumor invasion while indoleamine oxygenase has 
immnosuppressive activity 18.  Considering those aforementioned activities of ATP, 
removing extracellular ATP as soon as possible is necessary.  eNAMPT synthesizing 
plasma NMN could simultaneously play an important role in inhibiting tumorigenesis by 
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removing extracellular ATP.  It is critically important to investigate the in vivo kinetics of 
NMN biosynthesis and the environment required for NMN biosynthesis, particularly in 
the blood stream. 
In female ANKO mice, not only WAT and BAT but also the hypothalamus 
exhibit significant reductions in NAD+ levels, causing severe impairments of systemic 
insulin sensitivity and glucose-stimulated insulin secretion.  There have been multiple 
pieces of evidence that show how the hypothalamus is a major integration site for 
information received from neuronal, hormonal, and nutritional cues   In turn, it regulates 
glucose homeostasis by altering hepatic and skeletal muscle glucose fluxes as well as 
influencing insulin secretion from pancreatic β cells 19.  Collectively, these data support 
the idea that the adipose tissue-specific deficiency of NAMPT causes a functional defect 
in the hypothalamus by lowering its levels of NAD+.  We still cannot, however, rule out 
the possibility that the reduction of NAD+ biosynthesis itself in WAT and BAT could be 
the primary factor influencing the development of insulin resistance in female ANKO 
mice.  We could clearly answer this question if we could increase hypothalamic NAD+ 
biosynthesis by either overexpressing NAMPT or injecting NMN directly.  If impaired 
glucose tolerance or glucose stimulated-insulin secretion in female ANKO mice is 
improved, we could claim that low hypothalamic NAD+ is causative for these metabolic 
phenotype in female ANKO.  
  
Do gender differences affect energy metabolism via NAMPT?  
 Gender exerts profound effects on metabolism and endocrine function of the 
adipose organ.  Woman have a higher percentage of body fat than men and tend to store 
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adipose tissue preferentially in the gluteal-femoral region, as opposed to the male pattern 
of obesity concentrated in the visceral and abdominal depots.  Adipocyte metabolism in 
these depots also differs between genders 20-22.  Interestingly, these differences disappear 
with menopause and may be the cause of weight gain in the abdominal region after 
menopause 23, suggesting that female sex hormones play a significant role in these gender 
depot differences, leading to differences in adipocyte metabolism.  In addition, endocrine 
function of the adipose tissue also exhibits sexual dimorphism.  For instance, serum 
levels of adiponectin, an adipocyte-derived hormone, are similar in newborn mice, but 
after sexual maturation, circulation levels of adiponectin are twice as high in female mice 
compared with male mice 24.  Leptin also exhibits a similar sexual dimorphism 25.  These 
studies imply that gender differences of metabolism and endocrine function of the 
adipose organ could result in the differences in whole body energy metabolism between 
genders.  
Consistent to this notion, we also observed gender differences in metabolism in 
several lines of mouse models.  An increased dosage of SIRT1 in pancreatic β cells 
enhanced glucose-stimulated insulin secretion and improved glucose tolerance in both 
male and female beta cell-specific Sirt1-overexpressing (BESTO) transgenic mice at 3 
and 8 months of age 26.  As this same cohort of BESTO mice reached 18-24 months of 
age, glucose-stimulated insulin secretion by Sirt1 through repression of Ucp2 was blunted 
in both male and female BESTO mice.  However, NMN administration restored 
enhanced glucose-stimulated insulin secretion and improved glucose tolerance only in the 
aged BESTO females 27.  Similarly, Nampt+/- females, but not males, displayed decreased 
plasma levels of eNAMPT as well as impaired glucose tolerance and significantly 
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reduced glucose-stimulated insulin secretion, and these defects were completely restored 
by administration of NMN 3.  ANKO mice also showed similar gender differences as 
Nampt+/- mice did.  Female ANKO, but not male ANKO, exhibited lower levels of 
plasma eNAMPT compared to Namptflox/flox control mice.  They also showed severely 
impaired glucose tolerance and impaired glucose-stimulated insulin secretion 
accompanied with hyperinsulinemia, even though male ANKO also had mild 
hyperinsulinemia.  Since both Nampt+/- and ANKO females showed metabolic 
phenotypes different than males, I speculated that reduction in plasma eNAMPT could 
result in polycystic ovary syndrome (PCOS).  To prove this hypothesis, I compared 
histology of ovary structure between 3-month old Namptflox/flox mice and age-matched 
female ANKO mice that show more severe impaired glucose tolerance with 
hyperinsulinemia similar to PCOS patients than Nampt+/- mice.  I did not observe any 
obvious differences between them, unfortunately, although ANKO females tended to 
have higher plasma estrogen levels compared to Namptflox/flox mice (data not shown).  
Even though administration of NMN successfully ameliorated the glucose tolerance and 
glucose-stimulated insulin secretion completely in Nampt+/- and partially in ANKO mice, 
we still do not know if a reduction of eNAMPT protein itself is necessary for developing 
these abnormal metabolic phenotypes.  It would be of great interest to investigate which 
tissues cause impaired glucose metabolism in ANKO mice and to see whether increasing 
eNAMPT in plasma by injecting NAMPT protein improves impaired glucose metabolism 




 In my studies of the regulation and function of NAMPT in mammals, I attempted 
to shed light on the importance and the mechanism of NAMPT-mediated NAD+ biology 
underpinning type 2 diabetes.  I have found that NAMPT and NAMPT-mediated NAD+ 
biosynthesis is dramatically reduced in metabolically active tissues of a diet- and age- 
induced type 2 diabetes mice model, resulting in a disturbance of glucose homeostasis.  I 
have also demonstrated that eNAMPT secretion from adipocytes is regulated by SIRT1 
through its deacetylase activity in response to nutrient condition.  I have also 
demonstrated that Nampt knockout specifically in adipose tissues causes impaired 
glucose tolerance and functional detects in β cells secreting insulin, which is also 
observed in diet- and age- induced type 2 diabetes mice.  Interestingly, because the 
phenotype of both diet and age-induced type 2 diabetes mice models, as well as female 
ANKO mice, can be corrected by injecting NMN, it is highly possible that NMN could 
be used as therapeutic agent to improved type 2 diabetes.  
 Although having biochemical evidence of the existence of this NAD+ biosynthetic 
enzyme decades ago, its biological significance is only starting to be understood.  So far, 
many groups, including us, have unraveled many secrets of NAMPT including its 
biochemistry, structure, and role in physiology, but there are still many aspects that 
remain a mystery.  This thesis project has allowed me to understand the detailed 
mechanism of modulating NAMPT expression as well as eNAMPT secretion from 
adipocytes that affect metabolic homeostasis.  This thesis project has also led me to pay 
attention to new fields such as adipose tissue inflammation and sex differences and their 
affects upon metabolic phenotypes.  I believe that understanding these questions will also 
contribute to finding more fascinating discoveries in the field of metabolism.     
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